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SYNOPSIS 
This thesis sheds light on chronic pelvic pain in following areas: 1. Summarising prevalence 
of chronic pelvic pain 2. Exploring the risk factors in chronic pelvic pain, 3. Exploring beliefs 
on laparoscopic uterosacral nerve ablation and 4. Developing a protocol for a Multicentre 
randomised controlled trial of laparoscopic uterosacral nerve ablation.  
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EXECUTIVE ABSTRACT 
Objective 
This thesis has the following objectives:  
1. To estimate the prevalence of chronic pelvic pain (CPP) by means of a systematic 
review 
2. To generate pooled evidence on the aetiology of CPP by means of systematic review 
3. To undertake a questionnaire survey of practice concerning laparoscopic uterosacral 
nerve ablation (LUNA) in Europe 
4. To undertake a questionnaire survey of beliefs concerning effectiveness of LUNA  
5. To determine the effectiveness of neuroablation in CPP by means of a systematic 
review  
6. To develop a protocol for a prospective randomised controlled trial (RCT) to assess 
the effectiveness of LUNA in CPP 
Methods 
The work undertaken in this thesis was based on prospective study protocols using the 
following research methodologies: 
• Systematic reviews and meta-analyses to meet objectives 1, 2 and 5 
• Structured questionnaires to meet objectives 3 & 4  
• RCT to meet objective 6 
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Results 
1. There was significant variation among rates of all three types of CPP. Metaregression 
analysis showed that this heterogeneity was mainly due to non-representativeness of 
study sample and inadequacy of study methods. Meta-analysis of rates amongst high 
quality studies with samples representative of general population showed that 
prevalence of dysmenorrhoea (12 studies) was 59% (95% CI 49.1-71%, heterogeneity 
p<0.001), of dyspareunia (11 studies) was 13.3% (95% CI 8.8-20.3%, heterogeneity 
p<0.001) and of noncyclical pain (2 studies) was 6.2% (95% confidence interval (CI) 
3-12.6%, heterogeneity p <0.001).  
2. Age less than 30 years, low body mass index (BMI), smoking, early menarche (<11 
years), longer cycles, longer duration of bleeding or heavy menstrual flow, nulliparity, 
premenstrual syndrome, sterilisation, pelvic inflammatory disease (PID), sexual 
assault, emotional difficulties, psychological symptoms, suicidal tendency and 
somatisation were associated with increased risk of dysmenorrhoea. Younger age at 
first childbirth, exercise and oral contraceptives were associated with reduction in the 
risk of dysmenorrhoea. Peri/post menopausal state, PID, sexual abuse, anxiety and 
depression were found to be associated with dyspareunia. Drug/alcohol abuse, 
miscarriage, heavier menstrual flow, PID, previous caesarean section, pelvic 
adhesions/other pathology, childhood physical or sexual abuse, lifetime sexual abuse, 
anxiety, depression, hysteria, psychosomatisation were associated with an increased 
risk of noncyclical pelvic pain. 
3. Indications for LUNA, which included noncyclical chronic pelvic pain (CPP) (68%), 
dysmenorrhoea (66%), dyspareunia (39%) or endometriosis (60%), were similar 
across UK and rest of Europe. The European group performed LUNA more often 
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(62% vs. 21%), completely transected the uterosacral ligaments (56% vs. 36%) and 
ablated at a distance of more than 2 cm from its cervical insertion (50% vs. 21%) more 
frequently than the UK group. More experienced gynaecologists performed LUNA 
more for dyspareunia (46 % vs. 26%) and endometriosis (67% vs. 47%) and they 
performed complete transection (45% vs.26%) more often than their less experienced 
counterparts. 
4. The most widely held ‘prior’ belief, reflected in both questionnaire and numerical 
responses was that LUNA would have a small beneficial effect on pain. The credible 
limits of this belief were compatible with large reductions in pain as 60% of 
respondents believed a three-point improvement on VAS to be plausible. 
5. For the treatment of primary dysmenorrhoea, laparoscopic uterosacral nerve ablation 
(LUNA) at 12 months was better when compared to a control or no treatment. The 
comparison of LUNA with presacral neurectomy (PSN) for primary dysmenorrhoea 
showed that at 12 months follow up, PSN was more effective. In secondary 
dysmenorrhoea, along with laparoscopic surgical treatment of endometriosis, the 
addition of LUNA did not improve the pain relief while PSN did. Adverse events were 
more common for PSN. 
6. The LUNA trial protocol has been granted ethical approval. A total of 410 women 
have been randomised (September 2004). Interim analyses by an independent data 
monitoring committee have shown that the two groups are comparable in age, parity, 
type of CPP and baseline pain scores. 
Conclusion 
1. The variation in rates of CPP worldwide is explained by variable study quality. High 
quality literature revealed a high burden of disease. 
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2. Key gynaecological and psychosocial factors associated with CPP should be targeted 
in clinical evaluation of women with this symptom to individualise their management. 
3. There is variation in the surgical techniques of performing LUNA in Europe and the 
techniques vary according to operator experience. 
4. Among gynaecologists, there is a variation in beliefs about the effects of LUNA on 
pelvic pain, ranging from substantial benefit to slight harm. 
5. The evidence to recommend the use of nerve interruption in the management of 
dysmenorrhoea, regardless of cause, is still insufficient. Methodologically sound and 
sufficiently powered RCTs should be undertaken in future. 
6. The LUNA trial is the largest trial of neuroablation thus far. It is hoped that if the 
results of the trial are positive, women suffering from this common and difficult to 
treat condition will benefit from this simple operation. If the results are negative a 
reliable basis for discouraging the spread of this technique will have been provided. 
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 CHAPTER 1: INTRODUCTION 
 10
  
1.1 Definition of chronic pelvic pain 
There are many definitions for chronic pelvic pain (CPP). An existing systematic review 
observed that definitions for CPP vary greatly in the published literature.1 The definitions may 
consider duration of pain, location and type of pain and relationship to menstruation and 
sexual activity. One definition is ‘recurrent or constant pain in the lower abdominal region 
that has lasted for at least 6 months’.2 Another definition is: ‘nonmenstrual pain of 3 or more 
months duration that localizes to the anatomic pelvis and is severe enough to cause functional 
disability and require medical or surgical treatment’. 3 Although the choice of 3- 6 months’ 
duration within a definition is arbitrary, it does not carry the subjective anatomic or affective-
behavioural assumptions that other types of definitions have used. 4  
 
The International Association for the study of Pain have provided a specific definition for 
‘CPP without obvious pathology’: chronic or recurrent pelvic pain that cannot be sufficiently 
explained by an apparent physical cause;5 this is sometimes also called as the ‘pelvic pain 
syndrome’6 or ‘pelvalgia’.7 This definition of CPP does not specifically include pain 
associated with the menses or sexual intercourse. A common definition, including these 
issues, is: constant or intermittent, cyclic or noncyclic pain that persists for 6 months or more 
and includes dysmenorrhoea, deep dyspareunia and intermenstrual pain’.8 This definition will 
be used for CPP in this thesis. 
 
Dysmenorrhoea is the occurrence of painful menstrual cramps of uterine origin. 
Dysmenorrhoea is a very common gynaecological complaint that can affect up to 50% of 
women,9 and as such has a significant impact not just on personal health but also 
economically, through lost working hours.10 Dysmenorrhoea is commonly defined in two 
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 subcategories. When the menstrual pelvic pain is associated with an identifiable pathological 
condition, such as endometriosis, adenomyosis or pelvic adhesions reflecting previous 
inflammation, it is considered to be secondary dysmenorrhoea. In contrast, menstrual pain 
without organic pathology is considered to be primary dysmenorrhoea.11 According to 
standard gynaecological texts, primary dysmenorrhoea usually occurs at or shortly after (6 to 
12 months) menarche, when ovulatory cycles are established. The pain duration is typically 
48 to 72 hours and is associated with menstrual flow. In contrast secondary dysmenorrhoea is 
more likely to occur years after the onset of menarche and occur premenstrually as well as 
during menstruation. In practice, the accuracy of diagnosis depends on the availability and the 
use of diagnostic tools. 
 
1.2 Prevalence of chronic pelvic pain  
The prevalence rate of a condition in a population is the proportion of the population that has 
the condition at a specific point in time (point prevalence) or at some point in a time period 
(period prevalence). Prevalence rates for CPP will be difficult to ascertain in light of the 
varying definitions used in the literature as highlighted above. In a recent UK study, women 
aged between 12-70 years had an annual prevalence of 38/1000 of CPP defined as recurrent or 
constant pain in the area from navel down in the lower belly of at least 6 months duration, 
unrelated to periods, intercourse or pregnancy. This compares to the rate of asthma (37/1000) 
and chronic back pain (41/1000) in the community. 12  
 
Prevalence rates for dyspareunia and dysmenorrhoea are believed to be 8% and 45-97% 
respectively.1 This high prevalence reflects the disease burden in the community. Pelvic pain 
remains the single most common indication for referral to a gynaecology clinic accounting for 
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20% of all outpatient appointments. 3;13 Five percent of all new appointments are for CPP.14 
Pelvic pain has a major impact on health-related quality of life, work productivity and health 
care utilisation. It is also a major cause of workplace absenteeism. 15 An estimated 158 million 
pounds are spent annually on the management of this condition in the health service. 16 In the 
USA, $881.5 million are spent per year on its outpatient management. 17 From published 
studies it is estimated that approximately 40 per cent of all laparoscopies are done for CPP. 3  
 
Because CPP can reduce the quality of life and general wellbeing, there is a need to establish 
the true extent of the problem by performing a systematic review of all community based 
prevalence studies. One such review exists but it has been restricted to studies done in UK 
only. 1 
 
1.3 Aetiology of chronic pelvic pain 
CPP can have pathologic causes like endometriosis, adhesions, pelvic varices, etc. In addition, 
various social and psychological factors are reported to be associated with CPP18 such as 
personality traits, abuse in childhood or adulthood etc. 19  
 
The aetiology of primary dysmenorrhoea has been the source of considerable debate. Recent 
laboratory and clinical research have identified over-production of uterine prostaglandins as a 
substantial contributing factor to the painful cramps that are the major symptom of 
dysmenorrhoea.20 Prostaglandins are also implicated in secondary dysmenorrhoea, however 
anatomical mechanisms can also be identified, depending on the type of accompanying pelvic 
pathology. 21 Several primary studies, many with conflicting results, have made an attempt to 
identify possible predisposing factors for CPP. Those assessing psychological factors have 
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 been previously summarised in a meta-analysis,19 which, due to, language restrictions in its 
search 22;23 and lack of study quality assessment, 24 could not generate robust inferences. 
Studies evaluating physical factors in CPP have not so far been reviewed systematically to our 
knowledge. If the significance of both physical and psychosocial factors purported to be 
associated with CPP can be evaluated reliably, these may be more effectively targeted for 
clinical evaluation, prevention and treatment strategies and may help in designing research 
studies too. 
 
1.4 Anatomy of pain pathway and rationale for nerve ablation 
Pelvic pain is poorly understood entity. Descartes originally suggested that pain was a simple 
signal from peripheral pain neurons to the brain (the somatic theory). Eventually it became 
clear that pain is much more complex. The gate theory proposes that peripheral nociceptive 
signals can be modulated by neurotransmitters like serotonin and endorphins that can be 
linked with mood states.25 The pain may be evoked by depressive states as opposed to direct 
tissue irritation. Thus, interacting psychological and physical factors are likely to be present 
and attempt to separate one from the other is generally unrewarding.26  
 
Another theory, the diathesis-stress model, proposes that some patients are at increased risk of 
experiencing chronic pain due to acquired pre-existing vulnerabilities e.g. history of sexual 
abuse.27 The pelvic viscera receive neurons from both sympathetic (thoracolumbar) and 
parasympathetic (craniosacral) systems. The corpus, cervix and proximal fallopian tubes 
transmit pain through sympathetic fibres that arise from T10-L1. These fibres include neurons 
that are part of the uterosacral ligaments,28 and eventually merge into the superior hypogastric 
plexus (presacral nerve). The presacral nerve does not receive fibres from the ovaries and 
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lateral pelvic structures and logically presacral neurectomy, which involves the total removal 
of the presacral nerves lying within the boundaries of the interiliac triangle, could work only 
in midline dysmenorrhoea. 
 
The lateral pelvis transmits pain via nervi erigentes arising from S2-4. The presacral nerve 
divides into the hypogastric nerve that form the inferior hypogastric plexus, and this plexus 
divide into vesical, middle rectal and uterovaginal (Frankenhauser’s) plexuses. 
Frankenhauser’s plexus lies lateral to the uterosacral ligaments and medial to the uterine 
arteries and receives pain sensations only from the corpus and vagina. Interruption of these 
nerve trunks by uterosacral nerve ablation, as shown in figure 1.1 may alleviate pain.  
 
Figure 1.1: Pelvic nerve pathways and sites for laparoscopic uterosacral nerve ablation 
[C= afferent nerve supply of cervix (illustrated on right side of diagram); O= afferent nerve supply of ovary 
(illustrated on left side of diagram); U= afferent nerve supply of uterus (illustrated on right side of diagram). The 
permission to publish this figure has been kindly granted by Blackwell Sciences limited] 
 
Interruption of these nerve pathways has been used to alleviate pain by open abdominal or 
vaginal approach in the past, 29;30 but now this procedure can be performed less invasively via 
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 laparoscopic approach 31;32 and is often referred to as laparoscopic uterosacral nerve ablation 
or LUNA in short. This procedure is a topic for evaluation of practice patterns, beliefs and 
effectiveness in this thesis. 
 
1.5 Survey of Practice of LUNA 
Originally laparoscopic surgical experts were of the opinion that because of the divergence of 
the sensory nerve fibres and their ganglia as they leave the uterus, the uterosacral ligaments 
should be vaporised as close to the cervix as possible.32 However, recent anatomical studies 
have demonstrated that the greatest number of fibre bundles are at some distance from the site 
of attachment of the uterosacral ligament to the cervix 33;34.  Hence there is controversy about 
the optimal site for LUNA. Anatomical studies also suggest that the nerve fibres are dense at a 
depth of 3-15mm 33, thus the completeness of transection of the uterosacral ligament can also 
be expected to have an implication for the effectiveness of LUNA.  
Information on prevalent variations in the techniques regarding optimal site and depth of 
LUNA is currently unavailable. A previous survey showed that many UK gynaecologists 
claimed familiarity with the operative technique of LUNA 35 but it did not explore the 
differences in surgical techniques with respect to the site and depth of LUNA. Thus a survey 
to examine the indications and different surgical techniques of LUNA is needed to establish 
practice patterns. 
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1.6 Clinicians’ beliefs about effectiveness of LUNA 
Clinicians have varying degrees of certainty about effectiveness of treatments. It is ethical to 
initiate a clinical trial when there is collective clinical equipoise about the effectiveness of the 
available treatments.36 Prior beliefs are formed from indirect evidence (laboratory studies, 
epidemiology, extrapolation from similar treatments) and direct evidence (clinical trials, 
perhaps of an inconclusive nature). Surveys eliciting dichotomous ‘yes’ and ‘no’ responses to 
a question about effectiveness are limited because clinicians’ beliefs about a treatment usually 
amount to rather more than just “I believe it is effective” (or the converse). They may believe 
the treatment to be greatly or marginally beneficial (or harmful). Some may be rather more 
certain than the evidence apparently warrants, others may be uncertain to a degree that they 
believe the treatment may, in the due course, turn out to be either greatly beneficial or 
harmful.  
 
Formal measurement of beliefs about effectiveness can provide a clearer picture than the 
dichotomous responses. Formal measurements of ‘prior belief’ provide respondents with an 
opportunity to signal the magnitude of the expected effects and the relative probabilities of 
effects of different sizes. However, the published examples of collecting such information are 
sparse, in both obstetrics and gynaecology and in medicine.37;38 
 
A recent survey has indicated that there is wide variation in the practice and use of LUNA for 
treatment of CPP among clinicians, suggesting that collective clinical equipoise is present. 
The technique has been introduced without definite evidence but opinion regarding its use has 
not yet solidified, as 81% of gynaecologists performing LUNA stated their willingness to 
recruit patients in a trial to assess effectiveness of LUNA.35 However, this survey does not 
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 provide information on distribution of beliefs concerning effectiveness of LUNA in 
alleviating CPP. A structured survey to formally document the range of beliefs on 
effectiveness of this surgical treatment is required.  
 
1.7 Research Evidence on effectiveness of LUNA 
An overview of effectiveness of LUNA concluded that there is insufficient evidence to guide 
therapeutic decision-making with regard to LUNA.39 A systematic review of effectiveness of 
neuroablation undertaken in 2000 found insufficient evidence to recommend it in 
dysmenorrhoea.40 It also recommended the need for future randomised controlled trials 
(RCTs). This information needs to be updated in view of important trials that have been 
published since to ascertain whether the recommendation needs to be changed.  
 
The effectiveness of LUNA is currently being assessed in a trial. I worked as a research 
fellow coordinating this trial where I have helped develop and finalise the protocol. This will 
be presented in the thesis. 
 
1.8 Aims and objectives 
This thesis had the following objectives:  
1. To estimate the prevalence of CPP by means of a systematic review 
2. To generate pooled evidence on the aetiology of CPP by means of systematic review, 
3. To undertake a survey of practice concerning LUNA in Europe 
4. To undertake a survey of beliefs concerning effectiveness of LUNA  
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5. To determine the effectiveness of neuroablation in CPP by means of a systematic 
review  
6. To develop a protocol for a prospective randomised controlled trial to assess the 
effectiveness of LUNA in CPP 
These objectives are formulated as structured questions in table 1.1 
Table 1.1: Structured questions for each chapter of this thesis 
Chapter 
number 
Population Interventions / risk 
factors 
Outcomes Research 
designs 
Section A: Prevalence and aetiology of CPP 
2 Women at risk Prevalence by 
representativeness of 
studies 
Dysmenorrhoea 
Dyspareunia 
Noncyclical pelvic pain 
 
 
Systematic 
review (SR) of 
observational 
(cross sectional 
or longitudinal) 
studies 
3 Women at risk General (demographic) 
factors  
Gynaecological/ obstetric 
factors  
Psychological and social 
factors 
Dysmenorrhoea 
Dyspareunia 
Noncyclical pelvic pain 
 
 
SR of 
observational 
(cohort, case-
control or cross 
sectional) studies 
that provide 
comparative 
information on 
presence of risk 
factors in 
women with   or 
without CPP 
Section B: The Practice and beliefs concerning LUNA 
4 Gynaecologists 
in the UK and 
rest of Europe 
Structured questionnaire  Indications and techniques 
for LUNA across Europe 
Survey 
5 Gynaecologists 
collaborating in 
LUNA trial 
Structured questionnaire  ‘Prior beliefs’ on 
effectiveness of LUNA 
Survey 
Section C: Effectiveness of neuroablation 
6 Women 
undergoing 
laparoscopy for 
CPP 
Neuroablative procedures 
(LUNA or presacral 
neurectomy [PSN]) versus 
no neuroablation 
Pain relief  
Adverse effects 
Cochrane SR 
7 Women with 
CPP who need 
diagnostic 
laparoscopy 
LUNA versus No LUNA 
during laparoscopy  
Improvement in CPP, 
quality of life and sexual 
function 
Multicentre 
randomised 
controlled trial 
protocol 
LUNA= Laparoscopic uterosacral nerve ablation; CPP= chronic pelvic pain; SR= systematic 
review 
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 SECTION A: PREVALENCE AND AETIOLOGY OF CHRONIC 
PELVIC PAIN 
 
In this section, I summarise the evidence on prevalence and aetiology of chronic pelvic pain 
with systematic reviews of relevant studies in the following chapters: 
 
Chapter 2. Worldwide prevalence of chronic pelvic pain: A systematic review and meta-
analyses 
 
Chapter 3: Factors predisposing women to chronic pelvic pain: A Systematic Review 
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CHAPTER 2: WORLDWIDE PREVALENCE OF CHRONIC PELVIC 
PAIN: A SYSTEMATIC REVIEW AND META-ANALYSES 
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 2.1 ABSTRACT 
Objective 
A systematic literature review was performed to ascertain the prevalence of CPP according to 
the type of pain and to explore reasons for variation in its rates. 
Methods 
Medline (1966 to 2004), Embase (1980 to 2004), PsycINFO (1887 to 2003), LILACS (1982 
to 2004), Science Citation index and CINAHL (January 1980 to 2004) were searched to find 
potentially eligible studies. Hand searching of reference lists of the relevant studies was also 
carried out. Studies were considered if they had non-pregnant women without cancer and 
other specific disorders participating in surveys about rates of CPP. There were 178 studies 
(459975 participants) in 148 articles. Of these, 106 studies were (124259 participants) on 
dysmenorrhoea, 54 (35973 participants) on dyspareunia and 18 (301756 participants) on 
noncyclical pain.  Two reviewers, using a piloted form, extracted data independently on 
participants’ characteristics, studies’ methodological quality and rates of CPP. 
Results 
There was significant variation among rates of all three types of CPP. Metaregression analysis 
showed that this heterogeneity was mainly due to non-representativeness of study sample and 
inadequacy of study methods. Meta-analysis of rates amongst high quality studies with 
samples representative of general population showed that prevalence of dysmenorrhoea (12 
studies) was 59% (95% CI 49.1-71%, heterogeneity p<0.001), of dyspareunia (11 studies) 
was 13.3% (95% CI 8.8-20.3%, heterogeneity p<0.001) and of noncyclical pain (3 studies) 
was 10.4% (95% CI 9.1-25.7%).   
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Conclusion 
The variation in rates of CPP worldwide is explained by variable study quality. High quality 
literature revealed a high burden of disease. 
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 2.2 INTRODUCTION 
There is a need to establish the true extent of CPP for policy makers to consider in resource 
allocation and health care planning. In addition, these basic data are necessary to inform 
design of other research in this condition, like qualitative studies to establish well being and 
overall quality of life, genetic and environmental epidemiology to assess aetiology, and 
studies aimed at the development of new treatment strategies41. The epidemiological features 
of CPP have been generously reported in the worldwide literature. Majority of the studies are 
limited by small sample size and hence their inability to estimate prevalence precisely. The 
need to summarise this, however, has received scant attention42.  
 
A systematic literature review was performed to ascertain the geographical distribution of 
CPP, its prevalence according to the type of pain, and its variation within subgroups defined 
by age and development status of the country of origin whilst taking into account the quality 
of the studies. 
 
2.3 METHODS 
Our systematic review followed a protocol developed using widely recommended 
methodology. 43;44 
 
2.3.1 Data sources 
We searched general bibliographic databases: Medline (1966-2004), Embase (1980-2004) and 
PSYCHINFO (1887-2004). We also searched specialist computer databases: LILACS 
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(Literatura Latinoamericana y del Caribe en Ciencias de la Salud 1982 to 2004), CINAHL 
(January 1980 to 2004) and SCISEARCH (1974-2003).  
 
Our search term combination for electronic databases, based on published advice, was as 
follows: MeSH headings, text words and word variants for “pelvic pain”, “dysmenorrhoea”,  
“dyspareunia”, and “low abdominal pain” were combined with terms like “prevalence”, 
“community survey” and “incidence”. These were combined with terms representing relevant 
study designs e.g. cross-section, survey etc. according to recent recommendations45 for 
searching and the search was restricted to human and female (appendix 2.1). We also hand 
searched the bibliographies of all relevant reviews and primary studies to identify cited 
articles not captured by electronic searches. The search did not have any language restrictions. 
2.3.2 Study selection  
Studies on CPP were selected using the following predefined criteria: 
Participants: Non-pregnant women without cancer or other specific diseases participating in 
surveys about rates of CPP. 
Outcome: There is lack of consensus on the definition of CPP in the published literature.46 
We used a definition based on duration and nature of pain (constant or intermittent, cyclical or 
noncyclical pain, that persisted for 3 months or more8) and included three types: cyclical pain 
during menstruation (dysmenorrhoea), deep dyspareunia and noncyclical pelvic pain. Studies 
were included in the absence of information on duration of pain as long as it was explicit that 
cases of acute pain were excluded. 
Study design: Cross sectional studies that reported the prevalence of CPP. 
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 2.3.3 Data extraction and quality assessment 
Two reviewers extracted data independently, using a piloted form, on participants’ 
characteristics, study quality and rates of CPP. Data on studies not published in English were 
extracted by people with a medical background with command of the relevant language. We 
extracted information on whether studies evaluated dysmenorrhoea, dyspareunia and 
noncyclical pain symptoms individually or in combination. In some studies the existence of 
multiple symptoms amongst individuals could not be evaluated separately due to the structure 
of their questionnaires used and their manner of reporting and were excluded.  
 
The methodological quality of all selected papers was assessed to evaluate internal validity 
using the following attributes43: (a) Study design to determine if CPP assessment had been 
performed prospectively to minimise recall bias; (b) Adequacy of sampling by assessing 
whether recruitment of participants was random or consecutive or a convenience sample; (c) 
Sufficiently high response rate (>80%); (d) Use of a validated  measurement tool to ascertain 
CPP as this ensures that participants’ responses are a true representation of the underlying 
condition; (e) Sample size calculation so as to ascertain prevalence reliably. The studies were 
classified into high and low quality groups based on compliance with 3/5 quality criteria or 
more. Representativeness of the sample for general population (source of sample) was 
considered separately to methodological quality as this relates to external validity. This 
distinction is important because internally valid studies of women attending hospitals or for 
private health care checks may not be biased but they are less useful due to sampling of 
nongeneralisable population groups. 
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Numerators and denominators were extracted or estimated from each study for computing 
rates and confidence intervals (CI). In our review, prevalence measured how many women 
have CPP at a single point in time, i.e. point prevalence.47 Period prevalence, based on the 
number of women developing CPP during a defined period of time, was reported only in a 
few studies.  
 
2.3.4 Data synthesis 
For each study, we computed prevalence rates and their 95% CI according to the three 
different types of CPP. Rates of the different CPP were mapped to depict the variation in 
prevalence by country of origin. Heterogeneity was explored in the rates of CPP graphically 
using forrest plots of point estimates of rates and their 95% CI and statistically using 
Cochrane Q. Meta-regression explored if heterogeneity could be explained by variations in 
countries’ development status, participants’ average age, representativeness of the sample and 
methodological quality of the included studies.48 For development status we used the United 
Nations classification (developed, less developed and least developed) for countries. Study 
quality was assessed separately for individual items and scores. We performed both univariate 
and multivariate meta-regression analysis. Only high quality, representative studies were 
included in the final meta-analysis. Thus none of the hospital-based studies are included in the 
meta-analyses as they were not representative of the general population. Meta-analyses of log 
rates were performed weighting each study by the inverse of its variance49 using the random 
effects method50 (Stata 8 software) and the output was exponentiated. Publication bias was 
examined for, by plotting log rates versus their corresponding variances in a funnel plot. 
Funnel asymmetry was tested for using Egger’s test51 and Begg’s test.  
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 2.4 RESULTS 
Lists of included studies (appendix 2.2) as well as each included study’s salient features; 
methodological quality and accuracy data are given in Appendices 2.3,2.4 and 2.5 (in the 
accompanying CD ROM).  
Figure 2. 1: Study selection for systematic review on prevalence of chronic pelvic pain 
Total citations identified from electronic searches 1226
Papers retrieved for detailed evaluation: 225
1001 Citations excluded after screening abstract
Papers excluded: 109
No/ Insufficient /unclear data 5 
Not a primary data source 20
Not on prevalence of pelvic pain 50
Duplicate data 9
Unobtainable3
Study performed in : pregnant/postnatal women 8
: cancer 4 
: other specified disorders 7
: case-control study/case report  4
Primary papers included in systematic review: 148
178 studies (some papers  report more than one outcome/study):  
106 – dysmenorrhea
54 - dyspareunia 
18 -noncyclical CPP 
Searching of reference lists: 32
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The electronic search yielded a total of 1226 citations (figure 2.1). On examination of titles 
and abstracts, 228 were found to be potentially relevant and their full papers were obtained. 
The reference lists of these revealed 32 further citations. After reviewing these, 109 papers 
were excluded. The remaining 148 papers met the inclusion criteria, which provided data on 
459972 participants. 29 studies overlapped and reported more than one outcome. There is 
very little data (1/143 papers) available from the least developed countries. Study quality 
assessment (shown in figure 2.2 below) revealed deficiencies in many areas of methodology: 
Two (1.2%) studies met all five high quality criteria, 12 (7.1%) met 4/5 criteria. There were 
47 studies (27.8%) that met three or more quality criteria.  
Figure 2.2: Quality of studies included in systematic review on prevalence of chronic 
pelvic pain (Data presented as 100% stacked bars; figures in the stacks represent number of studies).  
 
 
 
 
The data on prevalence of CPP in included studies is summarised in figures 2. 3 – 2.5. Figure 
2.3 depicts the range of the number of studies and the percentage of pelvic pain found in those 
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 studies. Figure 2.4 shows the scatter of prevalence of the different types of pelvic pain with 
their confidence intervals. Epimaps in Figure 2.5 depict the available data on worldwide 
prevalence of different types of chronic pelvic pain by countries. 
 
Figure 2.3: Prevalence rates of different types of chronic pelvic pain amongst included 
studies 
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2.4.1 Dysmenorrhoea 
The prevalence rates ranged from 1.7%17 to 93.3%52 in 106 studies including 125249 women. 
Prevalence rates for cyclical pelvic pain in the UK reported were between 45% (12% 
reporting severe)53 to 97%54(14% severe) for any dysmenorrhoea in community based studies 
and between 41-62% in hospital based studies55;56. In other European countries it was 
similar.15;57 The lowest prevalence was reported in Bulgaria (8.8%) in women hospitalised 
with adnexitis between the ages of 19-41 years and the highest was in Finland (94%) in girls 
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aged 10-20 years.52 There was heterogeneity and the funnel plot for dysmenorrhoea was 
asymmetrical (Begg’s test P =0.02; figure 2.6) but not for representative studies (P=0.333) 
Metaregression showed validated measurement tool to be a significant factor to explain 
heterogeneity but not study quality score, representativeness, age< 25 years or development 
status of the country (developed vs. less developed vs. least developed). The prevalence of 
dysmenorrhoea in 54 representative studies was 46.7% (42.0-51.8%) as shown in figure 4. In 
12 high quality representative studies, the pooled prevalence was 59.1 % (95% CI 49-71%) 
 
Figure 2. 4: Data synthesis of studies on prevalence of different types of chronic pelvic pain.  
(See methods for details of meta-analysis. Heterogeneity p=<0.001 for all meta-analyses) 
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 2.4.2 Dyspareunia 
The prevalence rates ranged from 1.3%58 to 45.7%59 in 52 studies including 35973 women. 
The rates of dyspareunia varied from 1.1% in Sweden60 to 45%59 in US studies. In 26/52 
representative studies, the overall prevalence of dyspareunia was 10.3% (95% CI 7.2-13.4%, 
heterogeneity p<0.001). In 11 high quality representative studies, the prevalence of 
dyspareunia was 13.3% (95% CI 8.8-20.3%, heterogeneity p<0.001). Studies were markedly 
heterogeneous (P=0.000) and the funnel plot for dyspareunia was asymmetrical (Begg’s test P 
=0.001; figure 2.6) but not in representative studies (P=0.227). The representativeness of 
sample provided the main explanation for heterogeneity that was statistically significant in 
meta-regression analysis (appendix 2.6). Age under 60 was not a significant factor in 
metaregression (P=0.15).  
 
2.4.3 Non-cyclical pelvic pain 
The prevalence rates ranged from 4.0%61 to 43.4%62 in 17 studies including 299740 women. 
The funnel plot for noncyclical pelvic pain was asymmetrical (Figure 2.6; Begg’s test 
P=0.048; figure 2.6) but not for representative studies (Begg’s test P=0.88). Two recent high 
quality studies stated a 3 month prevalence of 15% in women aged 18-50 years in the USA17 
and 24% in ages between 12-70 in the UK.12 In less developed countries in South East Asia 
the prevalence rates varied from 5.2% in India, 8.8% in Pakistan to 43.2% in Thailand.62 The 
overall prevalence of noncyclical pain was 13.1% (95%CI 7.7-22.4%, heterogeneity p< 
0.001) in 7 representative studies. The prevalence of noncyclical pelvic pain in two high 
quality representative studies was 10.4% (95%CI 6.7-16.2%, heterogeneity p<0.001). The 
metaregression revealed that prospective design, adequate sampling strategy, sample size 
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estimation and high quality studies tended to describe lower prevalence of noncyclical pelvic 
pain though none of these were significant.  
 
 
Figure 2.5 Epimaps of worldwide prevalence of different types of chronic pelvic pain 
(dysmenorrhoea, dyspareunia and noncyclical pelvic pain respectively) 
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Figure 2.6: Funnel plots of the three types of pelvic pain prevalence studies 
 
2.5 DISCUSSION 
This is the first systematic review of the worldwide prevalence of CPP. It pooled rates of 
various types of CPP in high quality representative studies. Development status of the country 
did not affect the high rates of pain observed. The variation in rates of CPP worldwide is 
explained by variable study quality. High quality literature revealed a high burden of disease 
for dysmenorrhoea and dyspareunia. 
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 We believe that the findings of our study are valid as our review methodology was rigorous. 
A prospective review protocol was used and a concerted effort made to identify all the 
available evidence without language restriction. We made concerted efforts to report this 
systematic review as suggested by the MOOSE consensus statement (see table 2.5).63 Both 
the methodology and the rates of CPP varied among the included primary studies and 
explored the reasons for variations. For meta-analysis we included only high quality 
representative community studies in an attempt to summarise the prevalence in the general 
population. This review represents the best available evidence on the estimates of the 
prevalence of CPP at the time of writing and provides the best information available for 
targeting services at women suffering from pelvic pain.  
 
The variation in geographical distribution may be related to study characteristics, study 
quality, age groups included and definitions used rather than intrinsic differences between the 
prevalence of CPP between the different populations. Other plausible explanations might be 
differences in the prevalence of sexually transmitted infections, availability of medical and 
other resources or cultural differences. Although we have included studies from 1924 
onwards, majority of the studies are from 1980 onwards. The population demographics are 
unlikely to have undergone major changes over this period, making the studies relevant to 
current populations. Substantial differences or even complete absence of definitions, together 
with differences in age ranges of the populations studied, complicate the interpretation to a 
great extent.  
 
The information on which groups have increased rate of dysmenorrhoea, dyspareunia have 
implication for provision of services to policymakers in terms of provision of improved 
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access for these women to health care resources as well as the development of appropriate 
treatment protocols. Future epidemiological studies should ideally be prospective, with 
explicit definitions of the outcome and representative of the general population. The survey 
should use the validated measurement tools for validity and comparability of the results. 
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 CHAPTER 3: RISK FACTORS IN CHRONIC PELVIC PAIN: A 
SYSTEMATIC REVIEW AND META-ANALYSES 
 40
  
3.1 ABSTRACT 
Objective 
To evaluate the factors predisposing women to chronic pelvic pain, a common chronic 
condition. 
Methods 
Systematic review of all relevant studies without language restrictions was carried out. 
Studies were identified without language restrictions through Medline, Embase, PsycINFO, 
Cochrane Library, SCISEARCH, conference papers and bibliographies of retrieved primary 
and review articles (upto April 2004). 
Two reviewers independently extracted data on study characteristics, quality and results. 
Exposure to risk factors was compared between women with and without pelvic pain. Results 
were pooled within subgroups defined by type of pain and risk factors. Data were pooled to 
produce summary estimates of Peto odds ratio (OR) or standardised mean differences (SMD). 
Results 
There were 122 studies (in 112 articles) of which 63 (64,286 women) evaluated 54 risk 
factors for dysmenorrhoea, 19 (18,601 women) evaluated 14 risk factors for dyspareunia and 
40 (12,040 women) evaluated 48 factors for noncyclical CPP. Age less than 30 years, low 
body mass index (BMI), smoking, early menarche (<11 years), longer cycles, longer duration 
of bleeding or heavy menstrual flow, nulliparity, premenstrual syndrome, sterilisation, pelvic 
inflammatory disease, sexual assault, emotional difficulties, psychological symptoms, suicidal 
tendency and somatisation were associated with increased risk of dysmenorrhoea. Younger 
age at first childbirth, exercise and oral contraceptives and were associated with reduction in 
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 the risk of dysmenorrhoea. Age less than 50 years, peri/post menopausal state, PID, sexual 
abuse, anxiety and depression were found to be associated with dyspareunia. Drug/alcohol 
abuse, miscarriage, heavier menstrual flow, PID, previous caesarean section, pelvic 
adhesions/other pathology, childhood physical or sexual abuse, lifetime sexual abuse, anxiety, 
depression, hysteria, psychosomatisation were associated with an increased risk of 
noncyclical pelvic pain. 
Conclusion 
Key gynaecological and psychosocial factors associated with CPP should be targeted in 
clinical evaluation of women with this symptom to individualise their management. 
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3.2 INTRODUCTION 
There is wide variation in clinical evaluation of women with CPP. In some countries, like the 
UK, diagnostic laparoscopy is the standard investigation on referral to gynaecologists. 
Laparoscopy is negative in over 50% of cases, 3 so considering its invasive nature many 
clinicians reserve it for evaluation when non-invasive options have been exhausted.18 Thus in 
some countries, like in mainland Europe, empirical treatment is the standard initial 
management. 64 This variation in practice is in also due to uncertainty about effectiveness of a 
lot of available treatments to alleviate pathologic causes. 65-67 An initial strategy to uncover 
and treat pathologic causes like pelvic varices, adhesions and endometriosis first is not 
necessarily better than psychological management first. More fundamentally, the extent to 
which these pathologies are causally related to pain is itself uncertain as they overlap with 
psychosocial factors in a majority of CPP cases.68;69 Even laparoscopy is believed to have 
beneficial effects through psychological mechanisms.70;71 A better understanding of the 
relative contribution of various pathological, social and psychological factors to CPP19 may 
be helpful in clinical evaluation as well as in the development of prevention and treatment 
strategies and the design of future studies. 
 
A number of primary studies have sought to identify predisposing factors for CPP but often 
with conflicting results. A previous meta-analysis 19has summarised the evidence on social 
and psychological factors, but language restrictions in its search  and no assessment of the 
quality of studies included, 24 potentially limit its findings. No systematic review of the 
influence of physical and environmental factors in CPP has so far been undertaken. Hence a 
comprehensive systematic review of all studies was performed to evaluate risk factors for 
CPP. 
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 3.3 METHODS 
We first developed a protocol using widely recommended methods for systematic reviews of 
observational studies.44;63 
3.3.1 Data sources 
We searched general bibliographic databases: Medline (1966-2003), Embase (1980-2003) and 
PSYCHINFO (1887-2003). We also searched specialist computer databases: the Cochrane 
Library (2003:1) and SCISEARCH (1974-2003). Our search term combination for electronic 
databases, based on published advice,72 was as follows: MeSH headings, text words and word 
variants for “chronic pelvic pain”, “dysmenorrhoea”,  “dyspareunia”. Relevant terms for 
aetiological factors e.g. causal, odds ratio, relative risk etc. were used to combine with terms 
representing relevant study designs e.g. cohort, risk, case control studies, etc. and the search 
was restricted to human and female (see appendix 2 for details). We also hand searched the 
bibliographies of all relevant reviews and primary studies to identify cited articles not 
captured by electronic searches. 
3.3.2 Study Selection 
Studies on CPP that included a comparative group without pelvic pain and provided 
information on exposure to any risk factor were selected using the following criteria: 
Participants: Women at risk. 
Risk factors (exposures): General factors: Age, race, body mass index, smoking, 
occupational exposures, socio-economic status, education, sport activities etc. 
Gynaecological/obstetric factors: contraception, age at menarche, duration of menstrual flow, 
length of menstrual cycle, premenstrual symptoms, infertility, history of abortion or 
miscarriage, parity, age at birth of first child, previous caesarean section, previous pelvic 
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inflammatory disease (PID), presence of pelvic adhesions, varices, endometriosis, menopause 
etc. Psychological and social factors: history of childhood or lifetime physical, psychological 
or sexual abuse, anxiety, depression, borderline syndrome, psychosomatic symptoms, alcohol 
or drug abuse, unsatisfactory family relationship, history of death or divorce of parent at an 
early age, alcoholism in parent, disturbed puberty or childhood etc.  
Outcomes: Chronic (duration 3 months or more) noncyclical pain, menstrual pain 
(dysmenorrhoea) and pain related to intercourse (dyspareunia) localised in the lower abdomen 
and pelvis. 
Study designs: Observational (cohort, case-control or cross sectional) studies that provided 
information on the association of risk factors with CPP were included. Studies without 
comparative information on risk factors were excluded. 
 
Studies were selected in a two-stage process. One of us (PML) scrutinised the citations 
downloaded from the electronic searches and obtained full manuscripts of all citations that 
were thought to meet the predefined selection criteria or if there was uncertainty whether they 
were eligible for inclusion. Final inclusion or exclusion decisions were made when two of us 
(PML and LM) examined these manuscripts. In cases of duplicate publication we used all 
reports to assess study characteristics and quality, but only selected the most recent and 
complete versions for results. We applied no language restrictions. Two of us (PML and LM) 
independently assessed English manuscripts. People who had command of the language to 
allow data extraction assessed manuscripts in other languages (Chinese, Bulgarian, French, 
German and Japanese). We resolved any disagreements about inclusion or exclusion by 
consensus or arbitration by a third reviewer (KSK). 
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 Information on characteristics of exposures and outcomes were extracted. Some studies 
provided information on more than one outcome. For each of noncyclical pain, 
dysmenorrhoea or dyspareunia, we extracted data on separate forms. Wherever possible, 
exposure data and numbers of women with and without CPP were used to construct 2×2 
tables. In studies where the data on exposure were continuous, we abstracted means and 
standard deviation and numbers in groups with and without CPP. In some studies, where both 
of these data was absent, significance (p) values or correlation coefficients if quoted were 
extracted. We pilot tested the data extraction form on primary studies related to dyspareunia 
using two reviewers (PML and LM). Overall, the observer agreement regarding the various 
components of the data extraction form was 90-100%. We attempted to obtain missing data by 
contacting authors via email or post wherever possible.  
3.3.3 Methodological quality assessment 
We assessed all manuscripts that met the selection criteria for quality. We defined quality as 
the confidence that the study design, conduct and analysis minimised bias in the estimation of 
the effect of exposure to a risk factor on CPP. Our quality items were based on existing texts 
and checklists.44;63 
Bias can be associated with retrospective designs, non-consecutive or non- random participant 
recruitment, lack of blinding of assessors, partial verification of exposure to risk factors and 
outcome, overlooking temporality and lack of matching or adjusting for confounding factors. 
We considered a study to be of good quality if it used 1) prospective design 2) consecutive or 
random participant recruitment 3) ascertainment of exposures using validated instruments, 4) 
ascertainment of outcome by clinical evaluation with or without laparoscopy, 5) temporal 
relationship between exposure and outcome and 6) controlled for confounding factors. We 
classified studies into high or low quality categories by whether or not they fulfilled three or 
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more of the above six quality criteria. This is arbitrary cut off and not yet validated for non 
randomized studies. 
 
3.3.4 Data synthesis 
We tabulated information from each study stratified according to the three prespecified 
outcomes (noncyclical pelvic pain, dysmenorrhoea and dyspareunia). Results were computed 
separately for dichotomous and continuous data. For dichotomous data, effects in individual 
studies were assessed using standard Mantel Haenszel techniques, giving Peto odds ratios and 
confidence intervals.73 For continuous outcomes, the outcome measure of interest was the 
Standardised mean difference (SMD), the difference in means divided by the pooled standard 
deviation, which was used to allow the synthesis of data from studies where different scales 
were used.74 This method assumes that differences in standard deviations in the studies arise 
from differences in the scales rather than differences in population. However, even if this 
assumption is invalid, a consistent effect of an exposure between studies should still give 
qualitatively similar effects in all studies. In order to combine studies which assessed the 
same factors, but where some studies used continuous and some used dichotomous variables, 
we used the standard correction factor of π/√3 to convert from SMD to log odds ratio.73 
Results were displayed graphically using odds ratio (Forrest) plots with twin (continuous and 
dichotomous) scales where appropriate and heterogeneity between trials assessed using 
standard techniques.74 In order to allow somewhat for the possibility of false positive results 
arising out of multiple testing, 99% confidence intervals were used in all plots. 
Studies within each outcome were subgrouped according to risk factors and further according 
to control groups (pain free or with other pain). We also stratified by study quality. We 
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 assessed heterogeneity of individual effects within subgroup of studies graphically (using OR 
plots) and statistically (using chi square test) to help us decide how to proceed with 
quantitative synthesis.75;76 We explored for possible sources of heterogeneity by meta-
regression analysis77;78 using various explanatory variables defined a priori including age and 
study quality. When a variable was not explicitly mentioned, it was treated as "no" in the 
meta-regression analysis.  
 
3.4 RESULTS 
3.4.1 Literature identification, study characteristics and quality 
Figure 3.1 summarises the process of literature identification and selection. We identified 
5326 citations, from which 122 studies were selected for this review. 63 studies (64,286 
women) evaluated dysmenorrhoea, 15;52;55;61;79-137 19 studies (18,601 women) evaluated 
dyspareunia. 96;111;136-152 and 40 studies (12040 women) evaluated noncyclical pelvic 
pain.65;68;96;108;136;138;140;142;152-181 
 
Summaries of each study’s salient features are given in Appendix 3 (3.5-3.13 in CD ROM). In 
28/40 (70%) studies on noncyclical pelvic pain, 29/63 (46.03%) on dysmenorrhoea and 13/19 
(68.42%) studies on dyspareunia 3 or more quality criteria were satisfied. Multivariable 
metaregression analysis showed that sexual abuse was not associated with a particular type of 
CPP. In this analysis, poor quality studies had more prominent associations between abuse 
and pelvic pain than good quality studies (p=0.02). Multivariable analyses did not alter the 
significance of quality. Funnel plots of the analyses of abuse and pelvic pain showed 
asymmetry. 
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Figure 3.1: Study selection process for systematic review of studies of 
predisposing factors for chronic pelvic pain (see appendix for list of excluded 
studies) 
 
Total citations identified from electronic searches to capture articles 
on risk factors in chronic pelvic pain (n= 5563) 
Citations excluded after screening 
titles and/ or abstracts (n= 5361) 
Articles retrieved for detailed evaluation (n=202) 
From electronic search (n=153) 
From reference lists (n=49) 
Articles excluded    (n=91) 
Part duplicate data   (n=7) 
Data not extractable  (n=3) 
No control group (n=8) 
No group without exposure to risk factor (n=10) 
Not on pelvic pain (n=13) 
Unobtainable (n=3) 
No risk factors studied (n=6) 
Comment/case report/letter (n=13) 
Review articles (n= 28)
Articles included in systematic 
review (n=111)  
Some of these report several 
studies on different types of 
pain 
Studies included (n=122): 
Pelvic pain (n=40) 
Dysmenorrhoea (n= 63) 
Dyspareunia (n= 19) 
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Figure 3.2: Methodological quality of studies included in the systematic review of risk 
factors for chronic pelvic pain  
(Data presented as 100% stacked bars; figures in the stacks represent number of studies). 
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Figure 3.3: Metanalyses of risk factors associated with dysmenorrhoea 
(All multiple studies are heterogeneous, *** p<0.0001; **p<0.001; p<0.01) 
  
 
Figure 3.4: Metanalyses of risk factors associated with dyspareunia 
(All multiple studies are heterogeneous, *** p<0.0001; **p<0.001; p<0.01) 
3.4.2 Risk factors for CPP 
Thin (BMI<19) women, less than 30 years, nulliparous, smokers, ones who had early 
menarche (<12 years), longer cycles / duration of bleeding, irregular or heavy menstrual flow, 
presence of premenstrual symptoms, PID, sterilisation and history of sexual assault presented 
more frequently with dysmenorrhoea (figure 3.3). The risk of dysmenorrhoea increased with 
the number of cigarettes smoked per day (p<0.05 by trend test).89;182. Use of oral 
contraceptives, physical exercise, being married or in a stable relationship and higher 
Dyspareunia was commoner in women less than 50 years old, history of circumcision, PID 
and peri/postmenopausal. Women with dyspareunia reported anxiety, depression and sexual 
assault more frequently (figure 3.4).  
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Noncyclical CPP was associated with numerous general, gynaecological and obstetric factors, 
abuse and psychological morbidity notably previous miscarriage, longer menstrual flow, 
presence of endometriosis, PID, caesarean section scar, pelvic adhesions, childhood physical 
or sexual abuse, lifetime sexual abuse or any abuse, anxiety, depression, hysteria and 
somatisation (figure 3.5). On subgroup analysis, it was found that the abuse was more 
strongly associated with pelvic pain when the comparison group was painfree than when the 
controls had other pain like backache, headache etc. On comparing women with CPP (without 
and with obvious pathology) with pain free groups, across studies for psychological morbidity 
(depression, anxiety, neuroticism and somatisation), it was noted that psychological morbidity 
was more in women with pelvic pain irrespective of presence or absence of pelvic pathology 
on laparoscopy (p=0.03).  
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Figure 3.5: Metanalyses of risk factors in noncyclical pelvic pain 
(All multiple studies are heterogeneous, *** p<0.0001; **p<0.001; p<0.01) 
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3.5 DISCUSSION 
This review found key gynaecological and psychosocial factors that will be useful in clinical 
evaluation of CPP. Presence of pelvic pathology, history of abuse and coexistent 
psychological morbidity showed consistent associations with CPP. 
This systematic review comprehensively evaluated over 60 risk factors in 122 studies related 
to CPP. It was rigorously carried out with an extensive literature search without foreign 
language restrictions and with formal assessment of study quality to evaluate bias. It met 
quality criteria laid down in the MOOSE statement.63 It generated information on strength and 
consistency of associations of various risk factors with various types of CPP, so we could 
consider evaluation of some causal criteria. The variation and the poverty  of methodological 
quality of the included studies have implications for the validity of our findings. Retrospective 
studies are subject to incomplete or selective recall of previous events41. The exposure 
comparisons might not have been appropriate in some studies, e.g. non-sexual abuse group 
may actually be a non-sexually abused group of women who have experienced physical or 
psychological abuse, possibly increasing psychosocial distress and diminishing clinically 
relevant differences between the groups.183;184 Other concerns relate to the use of non-
standard measurement tools with questionable validity or reliability to discriminate between 
women with and without CPP. Ascertainment bias may arise by selecting control groups from 
women consulting for other conditions in the same setting, who did not have assessment like 
laparoscopy, so in them presence of pathology could not be assessed. An explicit definition 
for CPP was not uniformly used. These factors reduce the ability to confidently investigate 
causation.46 However, this is the best available evidence of the risk factors for CPP. 
Bias in reporting is a potential problem as studies may have looked at the interaction of 
several risk factors with CPP but published only those that were interesting or statistically 
 55
 significant. This could, conceivably, introduce bias in both directions—that is, analyses are 
probably equally likely to be published whether or not a particular factor indicates an 
abnormally high or an abnormally low risk. We decided to combine odds ratio and mean 
differences for risk factors where both types of results were expressed. This was done to avoid 
loss of strength of combined information as well as to avoid results from two analyses that 
could conflict and lead to an erroneous conclusion.73 
 
Certain study design features may impinge on the generalisability of our findings.41 Women 
included in many of the community based studies of dysmenorrhoea did not have detailed 
investigations to rule out pathology and so they cannot be classified strictly either as primary 
or secondary dysmenorrhoea.84 The need for imaging or laparoscopy to identify pathology in 
hospital setting means that in some studies, 99;118;185 associations between risk factors and CPP 
may be due to differences in health care seeking behavior and referral patterns compared to 
community settings.41 We feel that the associations observed for abuse, pathology and 
psychosocial morbidity are generalisable, because these were consistent across the studies 
from different geographical and age groups. 
Abuse was consistently and strongly associated with all types of CPP highlighting a possible 
causal role for it. Similar effect of these exposures on controls with other pain in contrast with 
painfree controls reflects the complex psychological interactions involved in the pain process 
or pathway.  
 
The mechanisms through which various pathologies might cause pain are not entirely clear. 
Pelvic inflammatory mediators and congestion may lead to all kinds of CPP in PID. 
Premenstrual symptoms are often associated with ovulatory cycles and hence release of 
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prostaglandins might explain the increased incidence of dysmenorrhoea in these women. 
Perimenopausal/postmenopausal states related hypoestrogenism is one of the explanations for 
dyspareunia in these women. 
 
Women with CPP had higher neuroticism, anxiety and depression scores and more sexual 
problems186 than controls, but this could be either a consequence of their pain or could 
increase the reporting of the pain. The case-control study design makes it difficult to 
distinguish between cause and effect. It seems the association of psychological morbidity with 
CPP could be due its link with non-organ specific pain, a conclusion supported by another 
meta-analytic review of psychological factors.  19
 In recent studies, abuse has been shown to be strongly associated with depression in women 
attending general practice,187 so one might find that women who are  abused are depressed 
and hence report pain more often. Similarly, it may be worry over menstrual distress that 
leads to heightened anxiety rather than anxiety itself that prompts dysmenorrhoea. It could 
also be that pathology, the root cause of dysmenorrhoea, may contribute to somatic imbalance 
that is expressed in raised scores on personality inventories.188 Our review, due to the study-
level nature of its analysis, is unable to disentangle these relationships. However, on the basis 
of strength and consistency of association we believe abuse and psychological morbidity to be 
at least as important as pathology for increasing the risk of CPP. 
 
Prospective cohort studies would be ideal study designs for delineating relationship between 
various exposures and CPP. Sexual abuse victims have been shown to use dissociative 
defenses to a greater degree189 and this increases the importance of using validated, structured 
assessment instruments while conducting future research on this group of women. As abuse 
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 seems to be commoner in control groups with other pain, to elicit the true association it might 
be necessary to perform future studies with pain free controls only. The development of non-
invasive diagnostic tools for some of the underlying somatic conditions that may account for 
CPP will help with unraveling of some of the risk factors further. If treatment of pathology in 
CPP shows no better outcome than without treatment, then probably there is a role for trials in 
psychological interventions. It would be rational to design intervention studies of use of 
psychological counseling, antidepressants and other modifiable factors in chronic pelvic pain. 
PID has emerged as a bigger risk factor than previously realized and it seems logical to 
establish this definitively and then explore preventative measures for CPP in women with 
definitive PID. One study design example is to measure chlamydia titers in women visiting 
STD clinic, treating those with high titers and then following all these women to establish 
whether the women who received antibiotics have reduced incidence of pelvic pain. Robust 
evidence from future aetiological studies could provide clues to experiment relevant treatment 
strategies for millions of pelvic pain sufferers. 
Key gynaecological and psychosocial factors associated with CPP should be targeted in 
clinical evaluation of women with this symptom to individualize their management and 
achieve a satisfactory outcome. 
(PML- Pallavi Latthe; LM- Luciano Mignini; KSK- Khalid Khan) 
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SECTION B: SURVEY OF PRACTICE OF LAPAROSCOPIC 
UTEROSACRAL NERVE ABLATION 
In this section, I examine the variation in current indications and surgical techniques for 
performing laparoscopic uterine nerve ablation (LUNA) in Europe assess the effect of 
operator experience on practice. I also explore gynaecologists’ ‘prior’ beliefs on effectiveness 
of laparoscopic uterosacral nerve ablation (LUNA) 
 
Chapter 4: Variation in practice of Laparoscopic uterosacral nerve ablation: A European 
survey 
 
Chapter 5: Measurement of ‘prior’ beliefs about effectiveness of laparoscopic uterosacral 
nerve ablation 
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CHAPTER 4: VARIATION IN PRACTICE OF LAPAROSCOPIC 
UTEROSACRAL NERVE ABLATION: A EUROPEAN SURVEY 
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4.1 ABSTRACT 
Objective  
To examine the variation in current indications and surgical techniques for performing 
laparoscopic uterine nerve ablation (LUNA) in Europe and to assess the effect of operator 
experience on practice. 
Methods  
Two groups were surveyed: I) UK gynaecologists (n=1569) and II) European Gynaecologists 
(n=301). A structured questionnaire was sent to the UK group and an identical email survey 
was sent to the European group.  
Results  
The questionnaire was returned by 719 (38% of 1870) of the gynaecologists contacted and 
173 (24%) performed LUNA. Indications for LUNA, which included noncyclical chronic 
pelvic pain (CPP) (68%), dysmenorrhoea (66%), dyspareunia (39%) or endometriosis (60%), 
were similar across UK and rest of Europe. The European group performed LUNA more often 
(62% vs. 21%), completely transect the uterosacral ligaments more frequently (56% vs. 36%) 
and more frequently ablated at a distance of more than 2 cm from its cervical insertion (50% 
vs. 21%) than the UK group. More experienced gynaecologists performed LUNA more for 
dyspareunia (46 % vs. 26%) and endometriosis (67% vs. 47%) and they performed complete 
transection (45% vs.26%) more often than their less experienced counterparts. 
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 Conclusion 
There is variation in the surgical techniques of performing LUNA in Europe and the 
techniques vary according to operator experience. 
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4.2 INTRODUCTION 
Chronic pelvic pain (CPP) is frequently investigated by laparoscopy.  Interruption of the 
nerve pathways in the uterosacral ligaments has been used to alleviate pain by open 
abdominal or vaginal approach in the past,29;30 but now this procedure can be performed less 
invasively via laparoscopic approach.32 Originally laparoscopic surgical experts were of the 
opinion that because of the divergence of the sensory nerve fibres and their ganglia as they 
leave the uterus, the uterosacral ligaments should be vaporised as close to the cervix as 
possible.32 However, recent anatomical studies have demonstrated that the greatest number of 
fibre bundles are at some distance from the site of attachment of the uterosacral ligament to 
the cervix 33;190.  Hence there is controversy about the optimal site for laparoscopic uterosacral 
nerve ablation (LUNA). Anatomical studies also suggest that the nerve fibres are dense at a 
depth of 3-15mm,33 thus the completeness of transection of the uterosacral ligament can also 
be expected to have an implication for the effectiveness of LUNA.  
 
Information on prevalent variations in the techniques regarding optimal site and depth of 
LUNA is currently unavailable. A previous survey showed that many UK gynaecologists 
claimed familiarity with the operative technique of LUNA 35 but it did not explore the 
differences in surgical techniques with respect to the site and depth of LUNA. Thus I 
undertook a large survey to examine the indications and different surgical techniques of 
LUNA among European gynaecologists. I was also interested in the preferences of 
gynaecologists for treating minimal-mild endometriosis in the context of LUNA.  
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 4.3 METHODS  
A postal survey of 1569 gynaecologists who were on the consultants’ database of the Royal 
College of Obstetricians and Gynaecologists (RCOG) was carried out between September- 
October 2002 (henceforth referred to as the UK group). I emailed the same survey to 301 
members of the European Society of Gynaecological Endoscopy (ESGE) who were on their 
email list (henceforth referred to as the European Group). I included a personalised letter to 
the clinicians informing them of the objective of the survey. 
 
The survey was designed to explore the differences in practice between the UK and the rest of 
Europe and between gynaecologists with varying levels of experience. To obtain information 
on various issues relating to the practice of LUNA, I included questions on indications, 
number of LUNA procedures performed, willingness to participate in a randomised trial to 
assess effectiveness of LUNA, techniques with regard to cutting modality, distance and depth 
of uterosacral ligament transection and any complications they had encountered. I also asked 
them about their routine practice of management of minimal-mild endometriosis encountered 
at laparoscopy.  
 
A Microsoft Access database was used to store the responses. The number of procedures 
undertaken by the gynaecologist defined experience. Following discussion with some RCOG 
gynaecologic endoscopy preceptors, I decided to use 20 procedures as a threshold to 
distinguish more from less experienced gynaecologists.  
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4.4 RESULTS 
4.4.1 Questionnaire responses 
As shown in table 4.1, of the 1569 questionnaires posted to the consultants on the database 
held by the RCOG, 661(42%) were returned. Of 301 email questionnaires sent to ESGE 
members, 58 (19%) were returned. The combined response rate was 38%. The UK group was 
three times more likely to respond than the European group (P<0.001). Responses to 
individual items were missing from some respondents. In total, 146 of the 173 (85%) 
respondents (86% and 83% in the UK and Europe respectively) who performed LUNA were 
willing to recruit women in a randomised trial to assess effectiveness of LUNA.  
4.4.2 Geographical variation in practice 
As shown in table 4.1, 137/ 661 UK respondents (21%) performed LUNA in contrast to 36/58 
(62%) of the European group (P<0.001). Indications for LUNA included chronic pelvic pain 
(68%), dysmenorrhoea (66%), dyspareunia (39%) and endometriosis (60%). The indications 
for LUNA were similar across UK and rest of Europe as shown in table 4.2. The different 
cutting modalities were used in similar proportions across the continent as is evident from the 
results shown in table 4. 3. As compared to 32% and 75% rates (some used both) of use for 
laser and electrodiathermy in the UK, the rates were 36% and 78% respectively in the rest of 
Europe. Compared to the UK group, the European group performed complete transection of 
the uterosacral ligament more often (56% vs. 36%; P = 0.05) and also transected it farther 
away from its cervical insertion more often (50% vs. 21%; P = 0.006).  
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 Table 4.1: Responses to the questionnaires on practice of Laparoscopic Uterosacral 
Nerve Ablation (LUNA) in the UK and the rest of Europe 
 
 UK  
n (%) 
Europe  
n (%) 
Total  
n (%) 
    
Number of questionnaires sent 1569 301 1870 
Number of questionnaires received (% of Q
sent) 
 661 (42) 58 (19) 719 (38) 
Number that do LUNA (% of Q received) 137 (21) 36 (62) 173 (24) 
Number Willing to Enter Patients into Trial (%
of those who perform LUNA) 
 116 (86) 30 (83) 146 (85) 
Speciality: Obstetrics Gynaecology 
                  Other  
128(93) 
09 (07) 
29 (81) 
07 (19) 
157 (91) 
16(09) 
Number of Procedures Performed in Career    
Fewer than 20 45 (33) 13 (36) 58 (32) 
20-49 60 (44) 10 (28) 70 (42) 
50-99 16 (12) 4 (11) 20 (12) 
100 or more 16 (12) 6 (17) 22 (13) 
Not stated 0 3 (8) 3(2) 
 
4.4.3 Complications of LUNA 
Of the 173 gynaecologists who performed LUNA, 169 responded to the question regarding 
complications with LUNA. Of these, 18 (13%) had encountered complications of LUNA; 16 
had come across short-term problems and 2 had seen long-term complications. The 
commonest complication stated was bleeding by six respondents and two respondents 
reported persistent pain. No one reported ureteric damage, prolapse or laparotomy. 
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Table 4.2 Comparison of indications for laparoscopic uterosacral nerve ablation 
(LUNA) 
Indications UK  
N (%) 
137 
Europe  
N (%) 
36 
Total  
N (%) 
173 
More  
Experienced 
 (112) 
Less 
Experienced 
(58) 
 
Chronic Pelvic Pain 
 
92 (67) 
 
25 (69) 
 
117 (68) 
 
72 (64) 
 
42 (72) 
Dysmenorrhoea 93 (68) 21 (58) 114 (66) 74 (66) 38 (66) 
Dyspareunia 52 (38) 16 (44) 68 (39) 52 (46) 15 (26) 
Endometriosis 82 (60) 21 (58) 103 (60) 75 (67) 27 (47) 
Endometriosis: mild only 24 01 25 15 10 
Endometriosis: mild or 
moderate 
 
14 
 
03 
 
25 14 03 
Endometriosis: moderate only 07 01 08 05 03 
Endometriosis: moderate or 
severe 
 
10 
 
05 
 
15 13 02 
Endometriosis: severe only 08 07 15 07 07 
Endometriosis: any severity 19 04 23 21 02 
Other Pelvic Pain 03 (2) 01 (3) 04 (2) 04 (2) 00 
 
4.4.4 Effect of experience on practice 
Table 4.3 compares various aspects of LUNA studied in the survey with respect to experience 
of the operating gynaecologist. Gynaecologists who had performed more than 20 LUNA 
operations used it more for dyspareunia (46% vs. 26%; P=0.01) and for endometriosis (67% 
vs. 47%; P = 0.01) than less experienced gynaecologists. They performed complete 
transection more often (45% vs.26%; P=0.02) than their less experienced counterparts.   
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 Table 4.3: Laparoscopic uterosacral nerve ablation (LUNA) techniques, management of 
minimal-mild endometriosis and comparison of techniques by experience 
  
 UK  
N (%) 
137 
Europe  
N (%) 
36 
Total  
N (%) 
173 
More  
Experienced  
112 
Less 
Experienced 
58 
Treatment of minimal-mild endometriosis  
Ablation with other
modality 
108 (79)  25 (69)  133 (77)  88 (79)  43 (74)  
Ablation exclusively  76 (55) 15 (42)   91 (53) 59 (53) 31 (53) 
Excision  23 (17)  15 (42)    38 (22) 27 (24)  10 (17)  
Excision exclusively   8 (06)   5 (14)   13 (08) 10 (9)  3 (05) 
Medical treatment  39 (28)    7 (19)    46 (27)  29 (26)  16 (28)  
Medical treatment 
exclusively 
17(12)   0   17 (10) 11 (10) 06 (10) 
Cutting modality used  
Laser 44(32)  13 (03)   57(33) 41 (37)  14 (24)  
Laser exclusively 20 (15)  8(22)  28 (16) 21 (19)  7 (12) 
Electrodiathermy 103(75)  28 (78)  131(76)  82 (73)  46 (79)  
Electrodiathermy 
exclusively 
62 (45) 15 (42)  77 (45) 43 (38) 32 (55) 
Scissors 20 (15)   8 (22)   28 (16)  19 (17)   9 (16)  
Scissors exclusively  3 (02)  6 (17)   9 (05)  1 (01)  2 (03) 
Harmonic Scalpel  15 (11)  03 (08)   18 (10)  13 (12)   5 (09)  
Harmonic scalpel 
exclusively 
 8 (06) 00   8 (05)  5 (04)  3 (05) 
How uterosacral ligaments (USL) are transected 
Completely 47 (36) 20 (56) 67 (41) 50 (45) 15 (26) 
Partially 82 (64) 16 (44) 98 (59) 58 (52) 39 (67) 
Distance from cervix for USL transection 
Less than 1cm 32 (23) 04 (11) 36 (21) 27 (24)   9 (16) 
1-2 cm 75 (55) 14 (39) 89 (51) 54 (48) 34 (59) 
More than /= 2 cm 30 (21) 18 (50) 48 (28) 31 (28) 15 (26) 
(The responses to some items were missing or more than one and hence the figures do not add up to the total 
number of respondents for some questions) 
 
4.4.5 Practice in minimal-mild endometriosis 
The approach to treatment of minimal-mild endometriosis encountered at laparoscopy was in 
favour of ablation. Of the 173 respondents, 133 (77%) ablated endometriosis. However 
38/173 (22%) excised it and 46/173 (27%) treated it medically. Some used one or more of the 
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above options concurrently. Compared to 108/137 (79%) of the UK gynaecologists, 25/36 
(69%) of the other European gynaecologists performed ablation in mild endometriosis. In the 
UK, 23/137 (17%) performed excision of which 8 respondents (6%) exclusively did only this 
for mild endometriosis. In contrast, the comparable figures for the rest of Europe were 15/36 
(42%) and 5/36 (14%) respectively. Among the UK group, 39/137(28%) offered medical 
treatment and 17(12%) of these offered only this option of treatment. In the European group, 
7/36 (19%) offered medical treatment but none of them offered it exclusively without surgical 
option. 
 
4.5 DISCUSSION 
A previous survey on this topic 35 was carried out on a limited sample of members of the 
British Society of Gynaecological Endoscopy only. It did not collect details of the methods of 
performing LUNA or current methods of managing minimal-mild endometriosis. The current 
survey was designed to obtain more in-depth knowledge of the practice across Europe. I used 
a short questionnaire and prepaid envelopes. I did not have enough resources to implement 
other strategies like coloured ink for the questionnaires, recorded first class post delivery for 
questionnaires, reminder letters with questionnaires for non respondents, monetary incentives 
and other such factors known to be associated with higher response191. This has a potential for 
introduction of bias by the “responding group”. There has been a trend towards reduction in 
response to questionnaire surveys.192 Thus it is not surprising that although I made all efforts 
within our means to enhance the return rate, I received replies from only 38% of 
gynaecologists.193;194  
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 This analysis and interpretation are limited due to a differential and low response rates. This is 
also the reason for inability to stratify the results by individual countries. The most likely 
reason for the differential responses between UK and the rest of Europe is the difference in 
the types of groups surveyed. All O & G consultants in the UK most of who are generalists 
were surveyed in contrast to gynaecological endoscopists in the rest of Europe. The 
differences in response rates could be due to the different methods of returning the 
questionnaires, which was by freepost in the UK whereas it was by email, or fax in the rest of 
Europe. There are several plausible reasons for non-response, including out of date addresses, 
lack of time in busy practice. It could also reflect on the poor general attitude of the specialty 
towards surgical research and evidence based practice. I observed that the proportion of 
gynaecologists in the UK performing LUNA in this survey was 24% compared to 45% in the 
last survey. An important difference between this survey and the previous one35 is that the 
first survey was on members of the BSGE which is a more focused group with special interest 
in Endoscopy than the group in the current survey comprising  of all the UK consultants in 
obstetrics and gynaecology. The absolute numbers performing LUNA were 137 in the current 
survey versus 113 in the previous survey35 indicating that perhaps the UK consultants who are 
members of BSGE continue to perform LUNA while other non-member UK consultants 
rarely do so. Our finding that higher proportions of European gynaecologists perform LUNA 
and excision of endometriosis could be due to the differences in the groups surveyed as 
alluded to before. It could also indicate different pattern of training in minimal access surgery. 
The difference in the depth and the distance of transection between the UK and the rest of 
Europe is difficult to explain but perhaps implies differences in the beliefs regarding the 
anatomy of the nerve plexuses. It is important to emphasise the apparent safety of the LUNA 
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procedure from the fact that none of the respondents reported ureteric damage or prolapse or 
laparotomy to control bleeding, which have been reported anecdotally.195;196 
  
A high proportion of gynaecologists wish to participate in a clinical trial to assess the clinical 
effectiveness of LUNA. This indicates that there is widespread clinical uncertainty in that the 
technique has been introduced without reliable evidence of effectiveness and so the opinion 
regarding its use is uncertain and variable. There is a need for an adequately powered, 
properly randomised trial to assess effectiveness of LUNA, a message that has been 
highlighted in several recent publications.39;197;198 This survey suggests that such a trial should 
also take into consideration the impact of differing prevalent techniques for this procedure.  
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 CHAPTER 5: MEASUREMENT OF ‘PRIOR’ BELIEFS ABOUT 
EFFECTIVENESS OF LAPAROSCOPIC UTEROSACRAL NERVE 
ABLATION 
 72
  
5.1 ABSTRACT 
Objective  
To explore gynaecologists’ ‘prior’ beliefs about effectiveness of laparoscopic uterosacral 
nerve ablation (LUNA). 
Methods   
A structured survey was used to gather information from participants on the distribution of 
their prior beliefs regarding the effects of LUNA on pelvic pain using a 10 point visual 
analogue scale (VAS). ‘Prior’ beliefs were captured both graphically and textually by 
responses to a questionnaire.  
Results  
None of the 25 gynaecologists responding to the questionnaire stated that LUNA would 
increase pain, while 2/25 gave numerical answers suggesting they believed that the 
intervention would worsen the pain. The most widely held ‘prior’ belief, reflected in both 
questionnaire and numerical responses was that LUNA would have a small beneficial effect 
on pain. The credible limits of this belief were compatible with large reductions in pain as 
60% of respondents believed a three-point improvement on VAS to be plausible. The standard 
deviations of expected mean change in VAS due to LUNA ranged from 0.52 to 1.64.  
Conclusion 
 Among gynaecologists, there is a variation in beliefs about the effects of LUNA on pelvic 
pain, ranging from substantial benefit to slight harm. 
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 5.2 INTRODUCTION 
It is ethical to initiate a clinical trial when there is collective clinical equipoise about the 
effectiveness of the available treatments.36 Prior beliefs are formed from indirect evidence 
(laboratory studies, epidemiology, extrapolation from similar treatments) and direct evidence 
(clinical trials, perhaps of an inconclusive nature). Surveys eliciting dichotomous ‘yes’ and 
‘no’ responses to a question about effectiveness are limited because clinicians’ beliefs about a 
treatment usually amount to rather more than just “I believe it is effective” (or the converse). 
They may believe the treatment to be greatly or marginally beneficial (or harmful). Different 
clinicians will admit varying degrees of uncertainty. Some may be rather more certain than 
the evidence apparently warrants, others may be uncertain to a degree that they believe the 
treatment may, in due course, turn out to be either greatly beneficial or harmful.  
 
Observing differences in practice or, as explored here, formal measurement of beliefs about 
effectiveness can provide a clearer picture than the dichotomous responses. Formal 
measurements of ‘prior’ belief provide respondents with an opportunity to signal the 
magnitude of the expected effects and the relative probabilities of effects of different sizes. 
However, the published examples of collecting such information are sparse, in both obstetrics 
and gynaecology and in medicine.199 
 
A recent survey has indicated that there is wide variation in the practice and use of 
laparoscopic uterosacral nerve ablation (LUNA) for treatment of chronic pelvic pain among 
clinicians, suggesting that collective clinical equipoise is present. The technique has been 
introduced without definite evidence but opinion regarding its use has not yet solidified, as 
81% of gynaecologists performing LUNA stated their willingness to recruit patients in a trial 
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to assess effectiveness of LUNA.35 However, this survey does not provide information on 
distribution of beliefs concerning effectiveness of LUNA in alleviating pelvic pain. Therefore 
a structured survey to formally document the range of beliefs on effectiveness of this surgical 
treatment was undertaken.  
In this chapter, I illustrate a method of collecting ‘prior’ beliefs of clinicians about possible 
effectiveness of an intervention. 
 
5.3 METHODS  
A survey was administered with oral explanation to a ‘captive’ group of participants in a 
Collaborators’ meeting of the LUNA trial200 in November 2002. The survey questionnaire is 
provided in the appendix. The aim was to obtain distribution of their beliefs about the likely 
effectiveness of LUNA in alleviating pelvic pain, compared to placebo i.e. laparoscopy alone. 
An example of how the survey of beliefs was explained is as follows: Suppose a clinician is 
asked to predict what the true benefit of LUNA is likely to be in reducing pain in suitable 
patients. Pain is to be measured using a Visual Analogue Scale (VAS) from 0 to 10, with 0 
indicating no pain and 10 indicating greatest conceivable pain. The outcome to be predicted is 
the mean extra change (before - after) in VAS scores in patients receiving LUNA, compared 
to the mean change in patients receiving placebo treatment i.e. laparoscopy alone. Thus, if the 
true mean change in VAS score in patients treated with LUNA is a reduction of 1.3 in pain 
score, while the true mean change in similar patients treated with placebo is an increase of 
0.2, then the true benefit from LUNA would be 1.5. On this scale, it is arbitrarily decided that 
the improvement of 0.5 to 1.5 points would be a small benefit, an improvement of 1.5 to 2.5 
points to be a moderate benefit, and an improvement of 2.5 points or more to be a substantial 
benefit.  
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Figure 5.1: A sample of a graphical elicitation of beliefs about the likely true effect of 
laparoscopic uterosacral nerve ablation (LUNA) compared to placebo (laparoscopy 
alone), in patients with chronic pelvic pain, as measured by change in 10-point visual analogue scale (VAS) 
scores (see text for details). This approach provided numerical estimation of ‘prior’ beliefs. 
True mean effect of LUNA
Increasingly likelyImpossible
(Placebo substantially better) -2.5
(Placebo moderately better) -2.0
(Placebo moderately better) -1.5
(Placebo slightly better)  -1.0
(Placebo slightly better)  -0.5
(No benefit over placebo)
(LUNA slightly better)  +0.5
(LUNA slightly better)  +1.0
(LUNA moderately better) +1.5
(LUNA moderately better) +2.0
(LUNA substantially better) +2.5
(LUNA substantially better) +3.0
Subjective probability of effect
 
Figure 5.1 provides an example of how the plots of beliefs were drawn. The participants were 
briefed on filling the numeric scale as follows:  If the participant believes that the most likely 
benefit from LUNA in suitable patients is (on average) zero (i.e. negligible benefit or harm), 
then he/she should first mark the zero benefit line somewhere towards the right of the page. If 
he/she believes that a mean 1.5 point or more disadvantage (i.e. LUNA moderately worse 
compared to placebo) is extremely unlikely, she should mark the –1.5 and –2.0 lines at or very 
close to the left end. Similarly, if he/she believes a mean benefit of 3.0 points or more (i.e. 
LUNA substantially better compared to placebo) is extremely unlikely, he/ she would mark 
the last line at the left-hand end. He/she then needs to consider how much less likely than zero 
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are mean changes of –0.5 and +0.5 are. Suppose he/she thinks +0.5 (i.e. a small benefit) is 
about half as likely, while –0.5 (i.e. a small harm) is about a quarter as likely, then he/she 
should mark these lines accordingly. All of the above details were briefly explained by a short 
presentation in the meeting. This procedure produced a distribution that represents the 
respondent’s beliefs - a “Bayesian prior”. 
 
We also asked the participants to describe their beliefs on the true mean effect of LUNA on 
pain, compared to standard treatment, by selecting a response from a number of statements or 
writing their own statement of beliefs. The graphical representations of the beliefs were 
‘triangulated’ with the textual statements to assess their compatibility. We used the 
respondent’s chosen statement describing their beliefs as a way of checking whether an 
elicited graphical representation really could be said to represent the respondent’s beliefs. To 
this end, three assessors (see acknowledgement) independently assessed the compatibility of 
textual statement and graphical representation for each respondent. The responses were 
processed and analysed using a spreadsheet. The mean weighted change in VAS was 
calculated for each respondent by multiplying the VAS with its likelihood (distance from left 
end in cm) and then taking average of all the values obtained. 
 
5.4 RESULTS 
The survey was distributed to 30 gynaecologists of whom 25 responded. Their distribution of 
the beliefs on basis of the textual responses is given in table 5.1. The distribution of numerical 
‘prior’ beliefs by graphical representation is summarised in figure 5.2. The range of means 
was –0.40 to 1.81. The standard deviations of expected mean change in VAS due to LUNA 
ranged from 0.52 to 1.64.  
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Table 5.1: Clinicians’ textual ‘priors’ beliefs on the effect of laparoscopic uterosacral 
nerve ablation (LUNA) on pain 
Response Number of clinicians 
(N=25) 
Harmful or no benefit 0 
Negligible benefit or harm (near 0 on VAS) 5 
Slightly beneficial (0.5 to1.5 reduction) 12 
Moderately beneficial (1.51-2.5 reduction) 4 
Substantially beneficial (2.5 or more reduction) 2 
Beneficial but unsure how much 0 
Unsure whether beneficial or not, but not 
harmful (0 or more reduction) 
1 
Unsure whether harmful or beneficial 1 
Other (own description if none fits well) 0 
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Figure 5.2: Graphical representation of numerical ‘prior’ 
beliefs
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The graphical representations of the beliefs when ‘triangulated’ with the textual statements as 
shown in figure 5.3, showed reasonable compatibility in that none were judged to be totally 
incompatible by any of the three assessors.  
The observed difference in mean change in VAS between the ‘compatible’ and ‘some 
incompatibility’ group was 0.27. The mean changes in VAS in both groups, however, is less 
than 2 points change on the VAS, which is the minimal clinically relevant difference assumed 
in the LUNA trial. The following results pertain to those respondents judged compatible on 
numeric and textual descriptions by all three assessors (10/25): expected mean change in VAS 
ranged from a small (0.1 points) increase to a substantial decrease (1.8 points).  The expected 
mean change in VAS due to LUNA on the numerical representation was 0.8 points reduction. 
The most pessimistic of these respondents predicted a mean change of 0.1 increase while the 
most optimistic respondent predicted a mean change of 1.8 point reduction in VAS scores. In 
responses where some incompatibility (15/25) between graphical and textual representation 
was observed (7/25 were thought to be compatible by two of the three assessors), the mean 
benefit was slightly less at a 0.51 point decrease on VAS. The observed difference in the 
mean change in VAS between the groups was 0.27 (confidence interval –0.17 to 0.72) with 
the ‘compatible’ group being more optimistic of the benefits of LUNA than the incompatible 
group, but this could simply be due to chance (P = 0.21).  
Figure5. 3 shows the correlation of textual and graphical beliefs with regards to the effects of 
LUNA. 
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Figure 5. 3: Agreement between graphical and textual representation of beliefs of effects of 
laparoscopic uterosacral nerve ablation (LUNA) 
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5.5 DISCUSSION 
There is variation in beliefs on the effectiveness of LUNA in pelvic pain, ranging from 
substantial benefit to slight harm. This study represents one of the very few attempts at formal 
collection of ‘prior’ beliefs from participants in a randomised controlled trial and possibly the 
first in gynaecological surgery. There might have been more variation if the sample surveyed 
was more representative of the general clinical opinion. The majority of respondents felt that 
LUNA would benefit the patient in terms of change in VAS but there was wide variation in 
the expected level of benefit. The clinicians did not agree about the benefits of LUNA and 
there was collective and reasonably balanced uncertainty201 - the main requirement for a 
randomised trial.36 The measurement of prior beliefs can be used for calculation of sample 
sizes as well as in Bayesian analysis of clinical trials.202;203 A double blind randomised 
controlled trial to assess effectiveness of LUNA is currently recruiting women with pelvic 
pain in the UK.200 We will be able to update these beliefs when the LUNA trial results are 
available and see whether clinicians’ beliefs change in line with Bayesian formulae. 
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The elicitation process used in the study was designed to be quickly self-completed with a 
minimum of exploration. The use of a textual statement to ‘triangulate’ with graphical priors 
is, a useful avenue to pursue, but one that is in need of further work. About half of elicited 
‘priors’ were unanimously agreed to be compatible with the textual statements. This 
performance may be in part due to remediable problems with the elicitation process, but it 
may point to a more fundamental truth - that for many respondents, substantial effort (from 
researcher and respondent) may be required before a valid prior can be elicited. The effort 
may include any or all of the following: re-examination of the evidence, extensive exploration 
of the task, feedback of the implications of elicited priors with the opportunity for revisions, 
discussion with colleagues etc. It would also have been useful to know at what expected level 
of benefit would the clinicians be inclined to offer LUNA to their patients.  
 
Methods of documenting distribution of beliefs about likely effects of a treatment need further 
development.204;205 Our survey is one such step in this direction. It would also be interesting 
for methodological researchers to compare the graphical and textual methods of collecting 
“Bayesian priors” and explore the factors that potentially will lead to better representation of 
the clinicians’ opinions.  
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SECTION C: EVIDENCE ON EFFECTIVENESS OF LUNA AND LUNA 
TRIAL PROTOCOL 
 
In this section I have endeavored to determine the effectiveness of neuroablation in CPP by 
means of a Cochrane systematic review and develop a protocol for a prospective randomised 
controlled trial to assess the effectiveness of LUNA in CPP  
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CHAPTER 6: EFFECTIVENESS OF NEUROABLATION IN 
RELIEVING CHRONIC PELVIC PAIN (DYSMENORRHOEA): 
UPDATE OF COCHRANE SYSTEMATIC REVIEW 
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6.1 ABSTRACT 
Objective 
To assess the effectiveness of surgical interruption of pelvic nerve pathways as treatment for 
chronic primary and secondary dysmenorrhoea. 
Methods 
The Cochrane Menstrual Disorders and Subfertility Group trials register (searched 9 June 
2004), CENTRAL (The Cochrane Library Issue 2, 2004), MEDLINE (1966 to Nov 2003), 
EMBASE (1980 to Nov 2003), and CINAHL (1982 to Oct 2003) were searched. Attempts 
were also made to identify trials from the metaRegister of Controlled Trials and the citation 
lists of review articles and included trials. The inclusion criteria were randomised 
comparisons of surgical techniques of interruption of the pelvic nerve pathways (both open 
and laparoscopic procedures) for the treatment of primary and secondary dysmenorrhoea. The 
main outcome measures were pain relief and adverse effects. The data was pooled in meta-
analysis to obtain Peto odds ratios with 95% confidence intervals.  
Results 
Nine RCTs were included in the systematic review. There were two trials with open presacral 
neurectomy (PSN); all other trials used laparoscopic techniques. For the treatment of primary 
dysmenorrhoea, laparoscopic uterosacral nerve ablation (LUNA) at 12 months was better 
when compared to a control or no treatment (Odds Ratio or OR 6.12; 95% confidence interval 
/CI 1.78-21.03). The comparison of LUNA with PSN for primary dysmenorrhoea showed that 
at 12 months follow up, PSN was more effective (OR 0.10; 95% CI 0.03-0.32). In secondary 
dysmenorrhoea, along with laparoscopic surgical treatment of endometriosis, the addition of 
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LUNA did not improve the pain relief (OR 0.77; 95% CI 0.43-1.39) while PSN did (OR 3.14; 
95% CI 1.59-6.21). Adverse events were more common for PSN than procedures without 
PSN (OR 14.6; 95% CI 5-42.5). 
Conclusion 
The evidence to recommend the use of nerve interruption in the management of 
dysmenorrhoea, regardless of cause, is still insufficient. Methodologically sound and 
sufficiently powered RCTs should be undertaken in future. 
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6.2 INTRODUCTION 
Dysmenorrhoea is a very common gynaecological complaint that can affect up to 50% of 
women. Although the use of both OCPs and NSAIDS206;207 has been very successful, there is 
still a 20 to 25% failure rate.21;208 Surgery has been a treatment for cases of dysmenorrhoea that 
fail to respond to medical therapy. When diagnostic laparoscopy is indicated, laparoscopic 
uterine nerve ablation (LUNA) and presacral neurectomy (PSN) are two surgical treatments 
that have become increasingly utilised in recent years and as described in chapter 1 (section 
1.4), both interrupt the majority of the cervical sensory nerve fibres, thus diminishing uterine 
pain.32 Observational studies have supported the use of LUNA for both primary and secondary 
dysmenorrhoea with either complete relief or substantial reduction in menstrual pain in the 
majority of subjects.209-215 PSN involves the interruption of a greater number of nerve 
pathways than LUNA, therefore it is a more complex procedure than LUNA, and entails more 
operative risk.216 However, despite these drawbacks the use of PSN is also supported by 
observational studies showing similar results to that of LUNA for both primary and secondary 
dysmenorrhoea. 217;218 
 
In order to determine the effectiveness of surgical interruption of pelvic nerve pathways (both 
open and laparoscopic UNA or PSN), I compared UNA/PSN to no treatment (where the 
control group is either no treatment or a recognised treatment which is also performed in the 
intervention group) and also explored if the effects varied according to: 1) primary or 
secondary dysmenorrhoea and 2) UNA or PSN. 
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6.3 METHODS 
A protocol for updating Cochrane reviews was adopted.219 
6.3.1 Data sources 
All reports that described (or might describe) randomised controlled trials of surgical 
interruption of pelvic nerve pathways (both open and laparoscopic) in the treatment of 
dysmenorrhoea were obtained using the search strategy developed by the Menstrual Disorders 
and Subfertility Group. Following were searched: 
(1) The Cochrane Menstrual Disorders and Subfertility Group trials register (searched 9 June 
2004). 
(2) The Cochrane Central Register of Controlled Trials (CENTRAL) on The Cochrane Library, 
Issue 2, 2004. 
(3) The electronic databases MEDLINE (1966 to April 2004), EMBASE (1980 to April 2004), 
and CINAHL (1982 to April 2004) using OVID software. 
(4) The metaRegister of Controlled Trials. 
(5) Citation lists of review articles and all included and excluded trials.  
 In most cases, the first or corresponding authors of included trials were contacted for 
additional information. The following keywords were used to search the above databases: 
dysmenorrhea, dysmenorrhoea, painful menstruation, pelvic pain/surgery/, laparoscopy, 
surgical procedures, laparoscopic denervation, uterine nerve ablation, presacral neurectomy.  
 
6.3.2 Study selection 
All prospective randomised controlled trials comparing surgical interruption of pelvic nerve 
pathways (both open and laparoscopic UNA and PSN) to no treatment, or other treatment, for 
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women with primary or secondary dysmenorrhoea were considered. Two reviewers (MP and 
PL) performed the selection of trials for inclusion after employing the search strategy described 
above. These trials included women of reproductive years with primary dysmenorrhoea (no 
identifiable organic pathology) or secondary dysmenorrhoea (identifiable specific pathology). 
Laparoscopic and open techniques are combined for these interventions, as there is some 
evidence to suggest they have similar ranges of pain relief for dysmenorrhoea.211;217 The 
outcome measures we looked at were: (1) Pain relief after treatment (at 6 months and more): 
Measurement with the VAS or other validated pain scales were studied and where these are not 
used other scales or dichotomous data as well as changes in pain intensity were also 
considered. (2) Adverse effects from the treatment (dichotomous data, number of participants 
with side effects) (3) Quality of life 
 
6.3.3 Quality assessment of included trials 
All assessments of the quality of trials and data extraction were performed independently by 
the two reviewers (MP and PL) using forms designed according to Cochrane guidelines. A 
third reviewer (NJ) resolved any discrepancies. Additional information on trial methodology 
and/or actual original trial data was sought from the authors of trials which appeared to meet 
the eligibility criteria but had aspects of methodology that were unclear, or where the data were 
in a form unsuitable for meta-analysis.  
 
We assessed the trials for the following quality criteria: method of randomisation, quality of 
allocation concealment until randomisation, presence or absence of blinding to treatment 
allocation after randomisation, explicit statement about the number of women randomised, 
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excluded or lost to follow up, whether an intention to treat analysis was done and whether a 
power calculation was done. 
 
6.3.4 Data synthesis 
Attempts were made to dichotomise the pain relief data in order to do sub-group analyses. 
Other pain scales were collapsed into dichotomous outcomes, pain relief or no pain relief. For 
example. if pain relief was measured on a scale of 0 (no pain)-5 (maximum pain imaginable), 
0-2 was considered as pain relief. 11 
 
Statistical analyses were to be performed according to the statistical guidelines for reviewers in 
the Menstrual Disorders and Subfertility Review Group.220 For the dichotomous data, results of 
each study were expressed as an odds ratio with 95% confidence intervals and combined for 
meta-analysis with RevMan software using the Peto-modified Mantel-Haenszel method. The 
outcome of pain relief is considered a positive consequence of treatment therefore a higher 
proportion of women with pain relief is considered a benefit (OR>1), whereas the outcome of 
adverse effects is a negative consequence therefore higher numbers are considered to be 
detrimental (OR <1). This needs to be taken into consideration when the summary graphs are 
viewed. 
 
6.4 RESULTS 
6.4.1 Literature identification, selection and characteristics  
A total of 288 articles were identified. Ten RCTs involving surgical interruption of the pelvic 
nerve pathways as treatment for dysmenorrhoea were selected. Out of these, one trial was 
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excluded from the review. The excluded trial221 compared laser laparoscopy (involving LUNA 
and surgical treatment of endometrial implants) to no treatment (expectant management only). 
Therefore due to the lack of a control group that had laser vaporisation only, the outcome data 
as a result of LUNA surgery could not be distinguished from the outcomes resulting from the 
laser vaporisation. 
 
Nine RCTs met the criteria for inclusion in the review. All the studies described clear inclusion 
and exclusion criteria (see appendix Table 7.1 of characteristics of included studies). All the 
trials included women between the ages of 18 to 50 years of age, and the majority of the 
studies' participants appear to have sought medical assistance for dysmenorrhoea. None of the 
trials gave clear information on the source of their women or how they were recruited into the 
studies. Two of the studies11;222 looked exclusively at women with primary dysmenorrhoea, 
excluding all participants with any pelvic pathology using a diagnostic laparoscopy. One study 
included women with dysmenorrhoea related to uterine myoma.223 One study included two 
patient groups, women with primary dysmenorrhoea and women with secondary 
dysmenorrhoea associated with endometriosis.224 The other studies included women with 
secondary dysmenorrhoea associated with endometriosis. Two of the included studies involved 
women with endometriosis included those with an AFS classification of stage III - IV 
endometriosis 225;226 one trial included women with only stage I – III, 227 and the other trials 
included all stages I – IV. 224;228;229 
 
Two trials11;224 compared laparoscopic uterine nerve ablation with diagnostic laparoscopy only, 
for women with primary dysmenorrhoea. Three trials 224;227;228 combined LUNA and laser 
treatment of endometriosis implants as surgical techniques and compared them with laser 
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treatment only, for women with secondary dysmenorrhoea. One trial compared LUNA and 
laparoscopic bipolar coagulation of uterine vessels with laparoscopic bipolar coagulation of 
uterine vessels only in women with dysmenorrhoea secondary to uterine myomas.223 Three 
trials compared presacral neurectomy combined with surgical treatment of endometriosis 
versus surgical treatment of endometriosis only as a control for treatment of secondary 
dysmenorrhoea. 225;226;229 The final included trial compared LUNA and LPSN as treatments for 
primary dysmenorrhoea. 222  
 
The primary outcome in all trials was pain relief. This was measured and reported in a variety 
of ways. Two studies used a 5-point pain scale.11;222 VAS were also used in some of the trials, 
however the length of the scales varied. One trial used a 10cm VAS as well as a 10-point pain 
scale.227 One study used a 10 point VAS (but only reported dichotomised data) and a 
multidimensional scale. This scale comprised 3 components: limitation of working ability, 
coexistence of systematic symptoms and need for analgesics.225 One study used a 100mm 
VAS230, and another simply reported whether pain relief did or did not occur. 226 The majority 
of studies also reported side effects; these were reported as the number of women who suffered 
any specific adverse events for example constipation.  
 
Outcomes were assessed at various time periods following surgery. In two trials 223;226, 
participants were assessed at 6 months, although one trial226 stated that participants were 
followed for a minimum of 42 months. One trial assessed participants at 3 and 6 months.227 In 
two trials 222;224 participants were assessed at 3 and 12 months. Two trials228;229 assessed 
participants at 6 and 12 months, although one of this228 extended follow up of some women for 
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up to 36 months. In the final two trials 11;225 all participants were followed up for at least 12 
months.  
 
Figure 6.1: Study selection process for systematic review of neuroablation in 
dysmenorrhoea (LUNA- laparoscopic uterosacral nerve ablation; PSN- presacral neurectomy) 
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6.4.2 Methodological quality of included studies 
All the included studies assessed comparability of the treatment and control groups at baseline, 
no appreciable differences in age, parity, condition or pain scores were reported. 
Five of the trials had adequate concealment prior to allocation. 224;226-229 Two studies had 
inadequate concealment, 11;223 due to the use of case numbers in the allocation process. Double 
blinding was used in six studies with blinding of the patient and the investigator, 11;223;224;227-229 
one was single blind, 226 and for the other trials blinding was unclear. Two trials 224;228 included 
an intention to treat analysis. A power calculation was performed in five studies. 224;225;227-229 In 
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one study, although the power calculation was done, the trial was stopped before the number of 
women needed was reached. 226  
 
Figure 6.2: Methodological quality of studies included in the systematic review of effectiveness of 
neuroablation in dysmenorrhoea (data presented as 100% stacked bars; figures in the stacks represent 
number of studies). 
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Follow up and withdrawal rates varied among trials. Two trials reported no withdrawals or 
losses to follow up.222;226 In four trials less than 15% of randomised participants withdrew or 
were lost-to-follow up.223;225;227;229 In one trial of 180 participants only 116 were analysed; 29 
became pregnant, 14 used OCP, 15 (8%) were lost-to-follow up, six women withdrew for other 
reasons. 228 In another trial of 18/39 women (46%) were excluded from analysis due to 
pathology at follow up. 11 
There were two trials with open PSN and none of open uterosacral nerve ablation. 
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6.4.3 Effectiveness of neuroablation 
6.4.3.1 LUNA versus control  
There were two studies comparing LUNA versus control for primary dysmenorrhoea.11;224 At 6 
months or less follow up there was no significant difference in pain relief (2 RCTs; n = 68; OR 
1.43, 95% CI 0.56 to 3.69). However longer-term pain relief (assessed at 12 months) showed a 
significant difference between the experimental and control groups (2 RCTs; n = 68; OR 6.12, 
95% CI 1.78 to 21.03). 
 
One trial 224 reported additional outcomes related to quality of life following treatment. 
Satisfaction rates at 12 months showed no difference between the groups (LUNA 15/18 vs. 
control 22/32; p>0.05). Information on the need for further surgery (one hysterectomy in the 
LUNA group and 2 in the control group), and the need for additional treatment (3 women in 
the no LUNA group were using OCP or Mirena), also indicated no difference between the two 
groups.  
There were three trials that compared LUNA with surgical treatment of endometriosis versus 
surgical treatment of endometriosis only. 224;227;228 At 6 months or less follow up there was no 
significant difference in pain relief (3 RCTs; n = 190; OR 1.03, 95% CI 0.52 to 2.02). Longer-
term pain relief also showed no significant difference between groups (2 RCTs; n = 217; OR 
0.77, 95% CI 0.43 to 1.39). 
 
 One trial 227reported comparable baseline pain scores, and at six months post-operative 
showed no significant difference between the experimental and control groups for 
dysmenorrhoea pain scores on the VAS scale (Mann-Whitney test, p=0.21). On the 10cm VAS 
 95
  
scale the experimental group pain scores at 6 months had a median of 4.8 (range 1-9.0), while 
the control pain scores had a median of 3.0 (range 0-9.8).  
Another trial found  no significant difference in pain relief between the treatment and control 
group following extended follow up of up to 36 months (1 RCT; n=116; OR 0.84, 95% CI 0.39 
to 1.80)228. The 12-month Kaplan-Meyer cumulative probability of recurrence of moderate to 
severe dysmenorrhoea was 33.7% for the experimental group and 27.55% for the control 
group. An intention to treat analysis on subject satisfaction showed that 68% of the 
experimental group and 73% of the control group were very satisfied or satisfied with 
treatment, while 32% of the experimental group and 27% of the control group were uncertain, 
dissatisfied, or very dissatisfied with treatment. No adverse effects were reported for either 
group. In this trial, additional quality of life data was collected. There were significant mean 
improvements in all scales; however at one year follow up the trial reported that there were no 
significant differences between groups.  
 
6.4.3.2 PSN versus control 
Three trials compared PSN with surgical treatment of endometriosis versus surgical treatment 
of endometriosis only.225;226;229 At 6 months (or less) follow up there was no significant 
difference in pain relief (1 RCT; n = 126; OR 1.23, 95% CI 0.50 to 3.00). Pain relief measured 
up to 12 months following treatment also showed no significant difference between treatment 
groups (2 RCTs; n = 197; OR 1.38, 95% 0.67 to 2.83). However in one trial, the authors 
originally collected information on the incidence, site and severity of pain and in analysis split 
their results into separate areas of pain.225 They interpreted their findings as showing a 
significant difference in the recurrence of midline abdominal dysmenorrhoea, with the 
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experimental group reporting what the authors interpreted as a significantly lower recurrence 
(p=0.06). There was a strong significant difference in the proportion of women with adverse 
effects from the treatment; the control group reported none but the PSN group reporting 13 
women with constipation, 3 with urinary urgency and 2 experienced a painless first stage of 
labour (OR 14.6, 95% CI 5.0 to 42.2). This trial also evaluated dysmenorrhoea on a 
multidimensional scoring system that included limitation of working ability, systemic 
symptoms, and need for analgesics. There was no significant difference between the treatment 
and control groups with both group showed a large reduction in symptoms (absent or mild 
symptoms - PSN 30/35 women, control 29/36 women). In another trial, where information on 
location of pain was collected, it was found that the experimental and control groups were 
significantly different in pain relief for midline abdominal pain (Fisher exact test, p= .028). 
However for back pain or lateral pain associated with dysmenorrhoea there were no significant 
differences between the groups. These results are based on only the eight randomised 
participants226.  
 
Figure 6.4: Results of metanalyses of effectiveness of neuroablation in dysmenorrhoea 
(LUNA- laparoscopic uterosacral nerve ablation, PSN- presacral neurectomy; shaded diamonds= statistically 
significant result; safety*: OR<1= LUNA is safer than LPSN and OR>1 = PSN has more adverse effects than 
control/no PSN)  
 97
  
Odds ratios
(95% confidence interval)
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LUNA vs. LPSN (1 study, 68 women)
PSN vs. control (2 studies, 197 women)
PSN vs. control (1 study, 126 women) 
LUNA vs.control (1 study, 116 women)
LUNA vs. control (2studies, 217 women)
LUNA vs. control (2 studies, 68 women)
Follow-up 12 months
LUNA vs. control (3 studies, 190 women)
LUNA vs. control (2 studies, 68 women) 1.43 (0.56, 3.69)
0.67 (0.17, 2.61)
0.10 (0.03, 0.32)
14.57 (5.04, 42.5)
0.02 (0.01, 0.06)
1.03 (0.52, 2.02)
0.77 (0.43, 1.39)
0.84 (0.39, 1.8)
PSN vs. Control* 
3.14 (1.59, 6.21)
4.52 (1.84, 11.09)
6.12 (1.78, 21.03)
Favours LUNA or PSNFavours Control or LPSN
Effectiveness in Primary dysmenorrhea
Follow-up 6 months
Effectiveness in Secondary dysmenorrhea
Follow-up 6 months
Follow-up 12 months
Follow-up 36 months
Safety*
 
6.5 DISCUSSION  
This review assessed the effectiveness of surgical interruption of pelvic nerve pathways in the 
treatment of dysmenorrhoea. There is insufficient evidence to recommend the use of nerve 
interruption in the management of dysmenorrhoea, regardless of cause. Adverse events were 
significantly more common for presacral neurectomy, however the majority were 
complications such as constipation, which may spontaneously improve.  
 
The systematic review was rigorously carried out with an extensive and rigorous literature 
search without foreign language restrictions and with formal assessment of study quality to 
evaluate bias. It met most of the quality criteria laid down in the QUOROM statement (see 
appendix 6.2).23 The review has been done adhering to a strict protocol.  
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Due to a small number of participants and predictable allocation of randomisation the results 
should be treated with caution. In the evaluation of the effectiveness of LUNA in treating 
secondary dysmenorrhoea a meta-analysis of the data is to be viewed with caution due to the 
relevant studies being heterogeneous in the baseline characteristics and stages of 
endometriosis. Quality of life measures were reported in only one study225 though 
improvement of this is the ultimate goal for the patient and the clinician. Overall the small 
number of participants who have been entered into randomised controlled trials on LUNA and 
PSN make it difficult to assess effectiveness in treating dysmenorrhoea. In the trials with 
negative results, inadequacy of power to detect a clinically important difference is an issue of 
concern. Overestimation of the expected clinical difference at the time of power calculation 
can lead to underestimation of the sample size, with the observed effect size showing wide 
confidence intervals indicating a potential for benefit as well as harm at the extremes of the 
confidence intervals. The other drawbacks of the included studies are single (fixed) block 
randomisation, lack of intention to treat analysis and limited generalisability of results due to a 
single centre trial.  
 
Laparoscopic PSN is a surgical procedure that requires a high degree of skill by an experienced 
pelvic laparoscopic surgeon trained specifically in this retroperitoneal operation. The presacral 
region may be highly vascular and the procedure carries major potential hazards for the unwary 
or inadequately trained surgeon. Conversely, although laparoscopic UNA must be performed 
precisely to avoid complications it should be within the scope of all competent pelvic 
laparoscopic surgeons. Not withstanding this fact, there is insufficient evidence to recommend 
the use of nerve interruption in the management of dysmenorrhoea and data from 
methodologically sound trials must be awaited before changing current practice. 
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There is a lack of good quality RCTs in all the comparisons examined in this review. The main 
issues are sample size and trial methodology. To help resolve the issue of effectiveness of 
neuroablation, clinicians may initiate good quality and adequately powered trials or participate 
in the ongoing multicentre trials. An individual patient data metanalysis may address the 
uncertainty by combining raw data from various studies included in this review as well as the 
data from ongoing studies.231 
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CHAPTER 7: A RANDOMISED CONTROLLED TRIAL TO ASSESS 
THE EFFECTIVENESS OF LAPAROSCOPIC UTEROSACRAL NERVE 
ABLATION (LUNA) IN CHRONIC PELVIC PAIN: THE TRIAL 
PROTOCOL 
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7.1 ABSTRACT 
Objectives 
The principal objective of the trial is to test the hypothesis that in women with chronic pelvic 
pain in whom diagnostic laparoscopy reveals either no pathology or mild endometriosis 
laparoscopic uterosacral nerve ablation (LUNA) alleviates pain and improves life quality at 
12 months follow up. 
Methods 
A multi-centre, prospective, randomised-controlled-trial will be carried out with blind 
assessment of outcomes in eligible consenting patients randomised at diagnostic laparoscopy 
to LUNA (experimental group) or to no pelvic denervation (control group). Postal 
questionnaires including visual analogue scale (VAS) for pain (primary outcome), an index of 
sexual satisfaction and the EuroQoL 5D-EQ instrument (secondary outcomes) will be 
administered at 3, 6 and 12 months. The sample size has been estimated as 450 patients in 
total using the hypothesis that LUNA will moderately alleviate pain symptoms (i.e. 0.3 SD 
difference in the pain scores on a VAS) compared to no intervention at one-year with 80% 
power at p= 0.05 and taking into consideration 20% loss to follow-up. The primary 
assessment of the effectiveness of LUNA will be from comparison of outcomes at the one-
year follow-up using intention to treat analysis. The medium-term and longer-term risks and 
benefits of LUNA will also be evaluated at 2, 3, 5 and 10 years. 
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Results 
Interim analyses in 2004 have recommended continued recruitment. A total of 410 women 
have been randomised (September 2004). The two groups are comparable in age, parity, type 
of chronic pelvic pain (CPP) and VAS baseline scores. 
Conclusion 
The LUNA trial is the largest trial of neuroablation thus far. It is hoped that if the results of 
the trial are positive, women suffering from this common and difficult to treat condition will 
benefit from this simple operation. If the results are negative a reliable basis for discouraging 
the spread of this technique will have been provided. 
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7.2 INTRODUCTION 
The transection of the uterosacral ligaments and the nerve plexuses it contains is a simple 
surgical procedure for pelvic pain. The original work by Doyle described vaginal and 
abdominal approaches to divide the attachments of the uterosacral ligaments to the cervix. 
29;30 With the wider use of minimal access therapy there is a renewed interest in the division 
of the Frankenhauser nerve plexus in the uterosacral ligaments laparoscopically using lasers 
or electro-diathermy. In an attempt to relieve patients’ symptoms clinicians frequently 
perform laparoscopic uterosacral nerve ablation (LUNA).  
However the effectiveness of this procedure has not been assessed objectively using 
methodologically sound research. I conducted a survey of UK O&G consultants and European 
gynaecologists associated with the European Society of Gynaecological Endoscopy in 2002 
(chapter 4) to determine the extent to which LUNA was being used in practice as also the 
differences in indications and techniques across Europe. I also conducted a survey of ‘prior 
beliefs’ (chapter 5) to measure beliefs about effectiveness of LUNA. The survey indicated 
that despite the lack of definitive evidence, many gynaecologists familiar with the technique 
were using LUNA as a therapeutic option. The systematic reviews to date39;232 have indicated 
the need for good quality trials to answer the question of effectiveness of this procedure in 
CPP. Crucially, the surveys conducted in 199835 and 2002, both indicated that 93 of 108 
(86%) gynaecologists currently performing LUNA were willing to recruit patients in a 
randomised trial of LUNA. In this situation equipoise applies i.e. the technique has been 
introduced without definite evidence but opinion regarding its use is not yet solidified. 
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Health technology assessment in surgical interventions requires an initial evaluation of the 
safety and stability of new interventions followed by randomised trials 233. The initial 
evaluative evidence 32;212 alone is not sufficient to assess the clinical effectiveness of LUNA 
for which randomised research remains the gold standard.  
Update of the Cochrane review (see chapter 6) has shown that the currently available 
randomised research evidence on LUNA is also inconclusive. Therefore further research is 
required to generate effectiveness evidence in the form of a high quality randomised 
controlled trial. 
7.3 METHODS 
7.3.1 The LUNA trial Objectives  
1. To test the hypothesis that in women with chronic pelvic pain in whom diagnostic 
laparoscopy reveals either no pathology or mild endometriosis (American Fertility Society 
score ≤ 5) LUNA alleviates pain and improves life quality at 12 months (principal objective). 
2. To test the hypothesis that response to LUNA differs according to the site and cause of the 
pain by two secondary analyses: (i) Women with central pain, (ii) women with no visible 
pathology. 
3. To explore the variation in LUNA's effectiveness and side effects at different periods of 
follow-up (3, 6, months and 1, 2, 3, 5 and 10 years). 
 
To meet the above objectives, a multi-centre, prospective, randomised-controlled-trial funded 
by WellBeing (CF/371),231 involving centres in the UK is being carried out with blinded 
assessment of outcomes in eligible consenting patients randomised and  blinded at diagnostic 
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laparoscopy to LUNA (experimental group) or to no pelvic denervation (control group). 
Postal questionnaires including visual analogue scale for pain (primary outcome), a sexual 
activity questionnaire (SAQ) and the EuroQol 5D-EQ instrument (secondary outcomes) will 
be administered at 3, 6 and 12 months. The primary assessment of the effectiveness of LUNA 
will be from comparison of outcomes at the one-year follow-up, although the medium-term 
and long-term risks and benefits of LUNA will also be evaluated by postal questionnaires to 
the women at 2, 3, 5 and 10 years after laparoscopy. 
 
Figure 7.1: The laparoscopic uterosacral nerve ablation (LUNA) trial schema 
Identification of eligible patient
•Chronic pelvic pain >6mth
•No obvious pathology
•Informed consent
Registration of patient for LUNA
•Complete pre-laparoscopy 
checklist 
•Simple fax to BCTU
Follow-up at 3, 6, 12, 24, 36, 60 and 
120 months by postal questionnaire
NO LUNALUNA
During laparoscopy
•Complete at-laparoscopy checklist
•Technically feasible
•Freephone BCTU to receive 
allocation/ Internet randomisation
Ineligible patients:
Follow-up at 6 & 12 months 
by postal questionnaire
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7.3.2 Participants 
All new patients presenting to the Gynaecology outpatient clinic with pelvic pain (cyclical or 
noncyclical) and/or dyspareunia, and requiring diagnostic laparoscopy for evaluation of these 
conditions, will be invited to participate200.  
Inclusion criteria 
 Pelvic pain of longer than 6-month duration. 
 Pain located within the true pelvis or between and below the anterior iliac crests. 
 Associated functional disability. 
 Lack of response to medical treatment. 
 Diagnostic laparoscopy planned. 
Exclusion criteria 
 Previous LUNA. 
 Mild, moderate and severe endometriosis (AFS score >5). 
 Previous surgery for endometriosis. 
 Previous surgery for pelvic inflammatory disease. 
 Previous hysterectomy. 
 Adnaexal pathology. 
7.3.3 Interventions 
Diagnostic laparoscopy plus uterosacral nerve ablation (experimental group) or laparoscopy 
without pelvic denervation (control group).  
LUNA will be carried out in a uniform manner by named surgeons in each of the participating 
centres following a common protocol as described in the standard surgical text.32 Routine 
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preparation will be made for a diagnostic laparoscopy with the patient under general 
anaesthesia. Following pneumoperitoneum, a laparoscope will be used to visualize the pelvis. 
Before embarking on operative laparoscopy an anatomical pelvic assessment will be 
performed to identify pelvic structures and pathology. At this stage patients with pathology 
outlined in the exclusion criteria will be excluded. It is expected that around 30% of women 
will be unsuitable for LUNA at operation. Women who are ineligible for the LUNA trial 
because of moderate to severe endometriosis, significant adhesions, significant pelvic 
inflammatory disease, other significant pathology or those for whom LUNA is not technically 
feasible should be registered with the Trial Office for follow-up only. The woman should be 
told that she was not eligible for the trial randomisation and the reasons why, and asked if she 
would agree to complete the follow-up questionnaires at 6 and 12 months. This non-random 
cohort will provide comparative data on the natural history of patients with chronic pelvic 
pain with significant pathology. Eligible patients will be randomised by a telephone call to the 
BCTU. 
 
Clear identification of the uterosacral ligaments is a prerequisite to treatment with lasers or 
electro-diathermy. The posterior leaf of the broad ligament will be carefully inspected to 
identify the course of the ureters, which on rare occasions could be particularly close to the 
uterosacral ligaments. Care will also be taken to note thin walled pelvic veins, which often lie 
lateral to the uterosacral ligaments. If accidentally punctured, they may cause troublesome 
bleeding requiring further endoscopic endocoagulation. The uterosacral ligaments will be 
identified by manipulation of the uterus in the right and left lateral planes. The ligaments will 
then be ablated with laser or micropoint electro-diathermy or endocoagulation depending 
upon the surgeons’ preference. The variation in the surgical techniques is as noted in Chapter 
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4. In a typical case, the ablation will start as close to the posterior aspect of the cervix as 
possible and continue for a minimum of 1 cm posterolaterally on either side. The aim of the 
procedure is to destroy the sensory nerve fibres and the secondary ganglia as they leave the 
uterus and come to lie within the uterosacral ligaments.  
The safe conduct of operative laparoscopy for LUNA requires the use of two ports, one for 
delivery of the energy source (laser or diathermy) and another for manipulation. These are in 
addition to the umbilical port used for the laparoscope itself. In contrast, diagnostic 
laparoscopy in women with no pathology requires only one port in addition to the umbilical 
laparoscopic port. This difference in number of ports has potential for introducing bias by 
compromising patient blinding to group allocation. A sham incision (see discussion) in the 
control group is used to overcome this problem. 
7.3.4 Trial procedures 
Consenting eligible patients will be randomised to diagnostic laparoscopy plus uterosacral 
nerve ablation (experimental group) or to no pelvic denervation at the time of diagnostic 
laparoscopy (control group).  
The subjects will be allocated to groups using a chance procedure, blocking and stratification. 
234 Stratified block randomisation will be employed to ensure that there will be nearly equal 
numbers of patients in the two groups within the prognostic subgroups, even if the study ends 
prematurely. Variable block size will be used to avoid any possibility of foreknowledge.  
Randomisation will be conducted using minimisation, stratified by the four variables: 
a. Presence or absence of some minimal pathology (minimal endometriosis ± ablation; 
adhesions requiring adhesiolysis only; minimal pelvic inflammatory disease) 
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b. Site of pain (presence of central pain or not) 
c. Parity of the woman (nulliparous or parous) 
d. Whether the woman is sexually active or not 
The first two variables form the prespecified subgroup analyses, and the other two variables 
are included as having impact on dysmenorrhoea and dyspareunia respectively. 
 
Treatment allocation will be issued at diagnostic laparoscopy, after the surgeon has inspected 
the pelvis and ensured that the patient fulfils all of the inclusion criteria and she does not have 
any of the exclusion criteria. Women may be randomised or registered into the study by 
telephoning the toll free Randomisation Line on 0800 953 0274 (+44 121 687 2319 from 
outside the UK) or by Internet randomisation at http://www.trials.bham.ac.uk/luna and 
clicking on the randomisation button. Passwords for Internet randomisation will only be 
allocated to centres with ethical approval. 
Following surgery, the surgeon fills in operation details on a post-surgery form. (Appendix 6) 
Patients will be kept blind to their treatment allocation until the follow-up in the trial is 
complete. However, there is a potential problem in the maintenance of blinding in the LUNA 
trial. As mentioned earlier, patients allocated to have LUNA will have the standard operative 
laparoscopy with three ports (one 10mm umbilical port and two 5mm lateral ports), whereas 
patients allocated to the control group under normal circumstances would have standard 
diagnostic laparoscopy with two ports (one 10mm umbilical port and one 5mm lateral or 
midline port). By noting the different number of incisions some patients might become aware 
of their group allocation and this might alter their response. In order to maintain patient 
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blinding, a sham 5mm skin incision is made superficially in a lateral port site. This approach 
in avoiding bias due to lack of blinding has been used in a previous trial of laparoscopic nerve 
ablation 221 and has also received ethical approval in this trial. 
The trial is being managed from the BCTU. Each investigating centre will carry out the study 
in accordance with the study protocol and to the Medical Research Council guidelines on 
Good Clinical Practice in Clinical Research (1998). Patients will be invited to participate if 
they fulfill all the inclusion criteria and do not have any exclusion criteria. They will be 
provided with a laparoscopy and LUNA trial information leaflet and signed consent obtained 
prior to laparoscopy. Consenting patients will be asked to complete the Enrolment 
Questionnaire and On Study Form. The final decision to enroll patient in the trial will depend 
on the findings at laparoscopy when the surgeon will perform LUNA or not after determining 
eligibility as shown in Eligibility Checklist and Randomisation Form. At the end of the 
procedure the surgeon will complete the Post Surgery Form (Appendix 6 contains all the 
forms used in this trial). All the three forms for each patient enrolled will be photocopied to 
keep a record at the participating centre and the originals will be sent to the BCTU, which will 
act as the coordinating centre. At 3, 6 and 12 months after enrolment, the Follow-up 
Questionnaire will be mailed to the patients with a pre-paid self-addressed envelope. 
Recruitment is expected to take 12 months (upto September 2005) and follow up for the main 
endpoints another 12 months. At completion of the main study further follow-up 
questionnaires will be mailed out at 24 and 36 months. 
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Table 7.1: Study Flow Chart 
Gynaecology 
Clinic 
Operating 
Theatre 
Postal Follow up (months/ years) Form/Questionnaire 
  3 6 12 2 3 5 10 
Patient information and 
consent (Appendix 6.1) 
X         
Eligibility Checklist and 
Randomisation form 
(Appendix 6.2)  
X X        
Enrolment Questionnaire 
(Appendix 6.3) 
X         
Surgery Form (Appendix 
6.4) 
 X        
Letter to GP (Appendix 
6.5) 
X         
Follow-up Questionnaire 
(Appendix 6.6) 
  X X X X X X X 
 
7.3.5 Outcomes 
The primary outcome measure will be based on VAS for assessment of pain.235 This 
technique involves use of a 10 cm line on a piece of paper representing a continuum of the 
patients' opinion of the degree of pain. It is explained to the patient that the one extreme of the 
line represents “no pain at all” while the other represents “as much pain as she can possibly 
imagine”. The subject rates the degree of pain by placing a mark on the line and scale values 
are obtained by measuring the distance from zero to that mark.  
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The secondary outcome measures will be assessment of sexual function and quality of life. 
The Sexual Activity Questionnaire (SAQ)236 will replace the Brief Index of Sexual 
Satisfaction (BISS) 237 for the assessment sexual function. This has been necessitated due to 
the poor acceptability and compliance with BISS in the pilot study. The SAQ has excellent 
internal consistency and test retest reliability. It also has excellent concurrent and construct 
validity and has been shown to be acceptable to women in other clinical trials. 238 In the 
questionnaire it will be clearly stated that the measure of sexual function covers material that 
is sensitive and personal. Participants will be reassured that their responses will be kept 
completely confidential and that if they do not wish to answer any questions, they will be 
allowed to leave the questionnaire blank.  
Health-related quality of life (HRQL) instruments are becoming powerful tools for outcome 
assessments in randomised trials. Quality of life instruments assess aspects of patient’s health 
status usually not grasped by conventional clinical indices; hence, they can be applied as 
complementary assessments together with VAS and SAQ. Quality of life has to be defined 
clearly and patient’s perception of normal performance serves a pivotal role in this context. 
HRQL instruments are administered with questionnaires assessing a number of different 
domains, i.e. areas of behavior or experience that the instrument is attempting to measure. 239 
Economic outcomes are often considered in clinical trials. LUNA is a quick, safe and 
inexpensive procedure for women already undergoing diagnostic laparoscopy. Our hypothesis 
is about a clinically important effect without an excess of complications. If the hypothesis is 
confirmed, then any benefits will essentially be “dominant” outweighing the relatively small 
costs of intervention. Therefore, we do not plan a formal economic evaluation at this stage. 
However, data on health resource use will be collected partly as effectiveness outcome 
measures (i.e. less need for medical care for pelvic pain indicates greater effectiveness), and 
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partly to allow an economic evaluation to be carried out, should significant complications 
occur. Other measures will include analgesic use, consultations at general practice and 
hospital, and time off work. Again these are both economic outcomes and indicators of 
residual pain. 
Postal Questionnaires to assess pain and sexual function will be administered at enrolment in 
the trial and then at 3, 6, 12, 24 and 36 months after laparoscopy. The outcomes at 12 months 
will be used to address the primary research question. This time interval is chosen because 
laparoscopy alone has a placebo effect for up to 3-6 months in some patients. 71;240 The 24 and 
36-month follow up will be used to monitor medium-term effects of the intervention. Existing 
participants in the trial who consented to 3 years of follow-up will be asked to consent to 
long-term follow-up (10 years) once they have reached the 3 year follow up time-point. 
Participants randomised after June 2003 are asked to consent to 10 years of follow-up at entry 
for long term follow up. 
The centres have been advised to fill an “adverse event form” in case of immediate and 
delayed complications if any are associated with the procedure.  
7.3.6 Sample Size and Power Considerations 
The sample size for this trial has been estimated using the hypothesis that LUNA will 
alleviate pain symptoms (i.e. reduce pain scores on a VAS) more often than no intervention at 
one-year following diagnostic laparoscopy. Cohen describes 'effect sizes' of 0.2 and 0.5 
standard deviations (SD) as 'small' and 'medium'.241 Interim analyses of the pilot study 
indicate that the SD of the difference in change in VAS scales between LUNA and no pelvic 
denervation groups will be about 4.0. This corresponds to small and medium effect sizes on 
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VAS of 0.8 and 2.0 respectively and is consistent with other studies of chronic pelvic pain, 
where clinically important symptom alleviation has been defined as a reduction in pain score 
of 2 or more 242. To confirm or refute a small to medium effect of LUNA (0.3 SD difference 
or 1.2 VAS points), based on ά=0.05 and β=0.2 (80% power), 175 patients in each group (i.e. 
350 patients in total) will be required. Considering a 20% loss to follow-up, the sample size is 
inflated to 210 patients in each group (i.e. 420 patients in total). 
7.3.7 Data Analysis 
The type of analysis will be based on Intention to treat principles. The main analysis to 
address the principal research questions will be conducted using the one-year follow-up data. 
The mean differences in VAS pain scores; sexual satisfaction and life quality scores in the 
two groups will be compared using a two-sample t-test. The rates of women with clinically 
significant (2 VAS point) alleviation of pain symptoms will also be compared producing a 
relative risk estimate with 95% confidence intervals (Mantel-Haenzel test). Baseline 
characteristics of the patients enrolled in the two groups will be compared to ensure that 
randomisation has produced comparable groups of patients. The use of additional treatment 
(co-intervention) for pelvic pain following LUNA or no pelvic denervation will be assessed 
for any systematic difference between the two groups.  
Subgroup analyses are limited by statistical power and can produce spurious results 
particularly if many are undertaken. Our literature review 39 and consultation with 
gynaecologists 35 suggests that the effectiveness of LUNA may be greater for central 
compared to non-central pain and if there is no associated pathology (i.e. no endometriosis). 
Therefore, we have chosen to limit secondary analyses to these subgroups only. The LUNA 
trial is powered to detect a small to medium overall difference and if a larger treatment benefit 
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is found then other subgroup analyses will be undertaken, appropriately cautiously. The 
LUNA trial is powered overall at 80% to detect a 0.3 SD difference in effect. Our pilot study 
shows that 60% patients have mainly central pain and 70% have no pathology. Hence, in the 
subgroup with central pain the power will be 80% to detect a 0.4 SD treatment effect. In the 
subgroup with no pathology the power will be 80% to detect a 0.35 SD treatment effect.  
 
7.4 RESULTS 
A study was undertaken with the objective of assessing its feasibility of a trial of LUNA. It 
has shown acceptability to patients. It has also established trial management procedures, 
piloted questionnaires, measured compliance and standardised operating procedures. A 
confidential interim analysis was reviewed by an independent data monitoring committee 
when the first 60 patients had completed 6 months follow-up (March 2001). The committee 
recommended that a larger study is needed for adequate statistical power in the trial to 
evaluate LUNA reliably.  
Bi-annual analyses of recruitment, compliance and loss to follow-up are being carried out for 
LUNA Trial Management Committee. An annual interim analysis of effectiveness was done 
in March 2003 and 2004 for confidential review by independent Data Monitoring Committee 
to determine whether the principal question has been answered and to monitor adverse events. 
It confirmed sample size estimation and recommended continued recruitment into the trial. 
 
Interim analysis has provided with the details of the baseline characteristics of women 
recruited in the trial upto August 2004 as described in the table below. 
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Table 7.2: Baseline characteristics of participants in the LUNA trial. Items marked * were, 
until recently, asked on the “On Study Form” rather than the randomisation form, and would therefore only be 
present if such a form were returned. Items marked ** were not asked on all versions of this form so information 
is necessarily not complete. 
 LUNA No LUNA 
Number randomised 200 206 
Treatment received* 
LUNA 
No LUNA 
Unknown 
 
182 
3 
15 
 
0 
186 
20 
Age: 
17-19 
20-29 
30-39 
40-49 
 
7 
64 
89 
40 
 
6 
74 
83 
43 
Adhesions Present 40 35 
Endometriosis 
None 
Minimal 
Minimal, Ablated 
 
150 
32 
18 
 
142 
42 
22 
Pelvic Inflammatory Disease 3 9 
Gravida* 
0 
1 
2 
3 
4+ 
Unknown 
 
56 
27 
36 
26 
22 
33 
 
75 
24 
31 
18 
26 
32 
Para* 
0 
1 
2 
3 
4+ 
Unknown 
 
71 
31 
43 
18 
13 
24 
 
75 
33 
43 
19 
14 
22 
Sexually Active* 
Yes 
No 
Unknown 
 
160 
30 
10 
 
152 
33 
21 
Dysmenorrhoea* 
Present 
Absent 
Unknown 
 
146 
43 
11 
 
144 
51 
11 
Dyspareunia* 
Present, Sexually Active 
Absent, Sexually Active 
Not Sexually Active 
Unknown 
 
127 
29 
30 
14 
 
110 
41 
33 
22 
Non-menstrual pain* 
Present 
Absent 
Unknown 
 
125 
58 
17 
 
126 
67 
13 
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 LUNA No LUNA 
Any visible pathology: 
Yes 
No  
 
15 
185 
 
11 
195 
Central dysmenorrhoea* 
Yes 
No 
Unknown 
 
93 
92 
15 
 
96 
96 
14 
Central dyspareunia* 
Yes 
No 
Unknown 
 
92 
88 
20 
 
89 
105 
12 
Central Non-cyclical pain* 
Yes 
No 
Unknown 
 
54 
126 
20 
 
58 
132 
16 
Irritable Bowel Syndrome** 
Yes  
No 
Unknown 
 
1 
76 
123 
 
0 
82 
124 
Previous Laparoscopy** 
Yes 
No 
Unknown 
 
1 
42 
157 
 
3 
45 
158 
Previous Surgery** 
Yes 
No 
Unknown 
 
0 
78 
122 
 
2 
81 
123 
Central pain: Any* 
Yes 
No 
Missing/Unclear 
 
130 
52 
18 
 
136 
54 
16 
 
 118
  
Table 7.3: Baseline VAS scores of pain, EUROQoL scores and sexual satisfaction scores 
of participants in the LUNA trial 
 
LUNA No LUNA 
Baseline VAS - dysmenorrhoea 
N 
Mean, SD 
 
 
170 
6.56 (2.63) 
7.2 (5 – 8.6) 
 
176 
6.7 (2.39) 
7.1 (5.2 – 8.4) 
Baseline VAS - dyspareunia 
N 
Mean, SD 
 
 
156 
5.9 (3.1) 
6.5 (4 – 8.5) 
 
169 
5.3 (2.97) 
5.7 (3 – 7.7) 
Baseline VAS – other pain 
N 
Mean, SD 
 
 
167 
5.7 (2.7) 
5.8 (4.1 – 8) 
 
177 
5.9 (2.73) 
6.5 (4.3 – 8) 
Baseline EuroQol Thermometer 
N 
Mean, SD 
 
 
153 
65.8 (22.75) 
70 (50 – 85) 
 
161 
67.9 (21.13) 
75 (50 – 85) 
Baseline EuroQoL Health Status 
N 
Mean, SD 
 
 
167 
0.56 (0.32) 
0.72 (0.23 – 0.8) 
 
167 
0.58 (0.3) 
0.73 (0.23 – 0.8) 
Baseline Sexual Satisfaction Score 
N 
Mean, SD 
 
 
136  
21.7 (14.85) 
18 (9 – 31) 
 
130 
23.8 (16.29) 
21 (21 – 34 
EuROQoL-European Quality of life questionnaire; SD- standard deviation; VAS- visual 
analogue scale 
 119
  
Figure 7.3: Quarterly recruitment progress in the LUNA trial 
Quarterly Recruitment Chart
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* Indicates incomplete quarter 
The graph above indicates the rate of recruitment divided in quarters in the LUNA trial. As 
seen in the graph, the recruitment increased once a dedicated research fellow was appointed to 
coordinate the trial. The recruitment is above target in most months (target is 15/month at 
present) and is expected to finish by April 2005 if the recruitment is carried on at the current 
rate of approximately 18/ month. This projection of recruitment is illustrated in the graph 
below (figure 7.5). 
 
The recruitment is highest in the centres where there is a Research fellow or funded research 
nurse sessions (BWH, Forth Park Hospital, Royal Hallamshire Hospital) 
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Figure 7.5: Recruitment Projection in the LUNA trial 
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Figure 7.4: Recruitment by collaborating centres until August 2004 
Recruitment by Centre
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7.5 DISCUSSION 
7.5.1 Main findings 
The acceptance rate for women invited to participate in the trial currently is 70%. The 
baseline characteristics of women randomised in the trial are not appreciably dissimilar. The 
follow up rate at present is 71% and efforts are being made to improve it.  
7.5.2 Quality of the trial 
The trial report will aim to convey to the reader the information needed to make informed 
judgments regarding the internal and external validity of the trial. LUNA trial complies with 
all the quality criteria laid down in the CONSORT checklist243 as is shown in table7.4 
 
LUNA Trial design ensures adequate methodological quality as it has taken care of selection 
bias (secure randomisation and allocation of participants), performance bias (blinding), 
measurement bias (valid and reliable pain measurement over long term) and statistical 
uncertainty (use of a power calculation) amongst other features. Stratified allocation is used 
so that chance imbalances in the stratification variable do not have an effect on the outcome. 
As has been previously pointed out in chapter 4, there are several acceptable variations in the 
practice and techniques of LUNA. Since response to treatment may depend on the surgeons' 
technique for laparoscopic uterosacral nerve ablation, analyses will be retrospectively 
stratified according to the surgeons participating in the trial. Allocation concealment is a 
crucial factor in avoiding bias in randomised trials.244 Although it is not possible to blind the 
surgeon, it is essential to keep the surgeon blind to the group allocation until after the 
irrevocable decision to enter the woman into the trial has been made. 
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Table 7.4 Consolidation of standards for Reporting Trials (CONSORT) checklist 
applied to the LUNA Trial Protocol 
Heading Subheading Descriptor Reported
Title  Identify the study as a RCT √ 
 
Abstract  Use a structured format √ 
 
Introduction  State prospectively defined hypothesis, clinical objectives and 
planned subgroup analysis 
√ 
 
 
Methods Protocol Describe: 
Planned study population with inclusion and exclusion criteria 
Planned intervention and their timing 
Primary and secondary outcome measures and minimum 
important differences and indicate how the target sample was 
projected 
Rationale and methods of statistical analysis, detailing main 
comparative analyses and whether they were completed on ITT 
basis 
Prospectively defined stopping rules (if warranted) 
 
√ 
√ 
√ 
 
√ 
√ 
√ 
 Assignment Describe 
Unit of randomisation 
Method used to generate allocation schedule 
Method of allocation concealment and timing of assignment 
 
 
√ 
√ 
√ 
 Blinding Describe mechanism, allocation schedule control and evidence of 
successful blinding among participants, outcome assessors, and 
data analysis 
 
√ 
 
 
Results Participant 
Flow& Follow 
up 
Provide a trial profile summarizing participant flow, numbers and 
timing of randomization assignment, interventions, and 
measurements for each randomized group 
 
N/A 
 Analysis State estimate effect of intervention on primary and secondary 
outcome measures including a point estimate and measure of 
precision (confidence interval) 
Describe prognostic variables by treatment group and any attempt 
to adjust for them 
 
√ 
 
 
 
√ 
Comment  State interpretation of study findings, including source of bias and 
imprecision (internal validity) and discussion of external validity 
including appropriate quantitative measures when possible 
 
√ 
 
 
 
 
 
Patients may also show a placebo effect if they know they have received the 
active treatment. The magnitude of placebo effects should not be 
underestimated. There is clear evidence that inadequacies of blinding in 
randomisation lead to exaggeration of treatment effect in randomised trials. A 
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second purpose of blinding is to prevent differences in other aspects of patient 
management introducing biases affecting the results.244 The patient’s GP will 
therefore be kept blind to treatment allocation.  Double blinding is not possible 
in LUNA, however, as the surgeons performing the surgical intervention on the 
patients will be aware of the group allocation. However, the likelihood that this 
will lead to bias in outcome assessment is low as the patient outcome 
assessments in this study will be conducted by self-administered questionnaires, 
avoiding any possible bias from surgeons’ knowledge of group allocation. 
Pain is difficult to measure, partly because it is accompanied by other 
sensations and partly because the reaction component affects the judgment of 
the pain regardless of the intensity of the stimulus. A measure of pain is 
nevertheless essential to the outcome of this clinical trial. VAS originally 
devised as measures of well being,245 have been successfully adapted to 
measure pain and have been established to be reproducible and accurate.235;246 
VAS has commonly been used in measurement of chronic pain. 247 All the 
studies of LUNA included in systematic reviews so far have used this measure, 
or its variation, for assessing outcome. Individual pain scores have sufficient 
psychometric strengths to be used in chronic pain research involving group 
comparison designs.248 Sexual function is an important aspect of life quality in 
patients with pelvic pain. Pain itself is an anti-aphrodisiac, and together with 
discomfort and altered self-image, it impacts upon sexual function. 249 Its 
assessment in an objective manner is therefore an important part of the LUNA 
trial. There are several sexual function instruments, with high levels of 
reliability, validity and responsiveness, which yield comparable results across 
 124
  
occasions and individuals, making them suitable for monitoring therapeutic 
progress in randomised research. 249 
When there is uncertainty about the appropriate therapy, scientific clinical trials 
are the best scientifically ethical way to resolve uncertainty and thereby benefit 
both the individual patients and all others concerned in their care. 250 The need 
for a “sham” incision in this trial is the main ethical issue and it is required 
because without it the patients cannot be kept blinded. The purpose of blinding 
is to prevent various biases from affecting the results. The need for blinding in 
surgical trials has been emphasized in the medical literature 251 and there is 
empirical evidence that inadequacies of blinding in randomisation lead to 
exaggeration of therapeutic efficacy in randomised trials.244 Blinding of patients 
in surgical trials is clearly indicated when the intervention primarily treats 
symptoms and when the outcomes are based on patients' own assessment. 
LUNA is an intervention for treating chronic pelvic pain (a diagnosis based on 
symptoms) and the outcome assessment is based on patients’ responses on a 
VAS and a quality of life instruments. Hence, the use of a “sham” incision is 
justified if bias is to be avoided in the LUNA trial and this approach has been 
used in a previous trial of LUNA.221 Ethical approval for the LUNA trial 
procedures has already been obtained from the Multicentre Research Ethics 
Committee. 
 
The LUNA trial is already the largest trial of neuroablation. It is hoped that if 
the results of the trial are positive, women suffering from this common and 
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difficult to treat condition will benefit from this simple operation. If the results 
are negative a reliable basis for discouraging the spread of this technique will 
have been provided. 
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CHAPTER 8 SUMMARY 
 127
  
8.1 Summary of findings 
In this thesis, I have collated existing knowledge on prevalence and aetiology of chronic 
pelvic pain and effectiveness of pelvic neuroablation by means of thorough systematic 
reviews. I have surveyed practice of LUNA in Europe, developed questionnaire to collect 
‘prior beliefs’ on effectiveness of LUNA and LUNA trial protocol. Below, I reproduce the 
table of structured questions from Chapter 1 (Table 1.1), adding a final column of results from 
the various chapters of this thesis:  
 
 128
  
Table 8.1: Findings of the objectives in the thesis 
 
Objective A: To summarise the evidence on prevalence and aetiology of chronic pelvic pain with systematic reviews of 
relevant studies 
Cha
pter  
Population Comparison  
 
Outcomes Research Design Findings 
2 Women at 
risk 
Prevalence by 
representative
ness of 
studies 
Dysmenorrhoea 
Dyspareunia 
Noncyclical pelvic 
pain (CPP) 
 
Systematic review 
(SR) of observational 
(cross sectional or 
longitudinal) studies 
There was significant variation among rates 
of all three types of CPP. Meta-analysis of 
rates amongst high quality studies with 
samples representative of general 
population showed that prevalence of 
dysmenorrhoea (12 studies) was 59% (95% 
CI 49.1-71%), of dyspareunia (11 studies) 
was 13.3% (95% CI 8.8-20.3%) and of 
noncyclical pain (2 studies) was 6.2% 
(95% confidence interval (CI) 3-12.6%, 
heterogeneity p for all three values was 
<0.001).  
 
3 Women at 
risk 
General, 
Gynaecologi
cal/ 
obstetric,  
Psychologic
and social 
factors 
Dysmenorrhoea 
Dyspareunia 
Noncyclical 
pelvic pain 
 
SR of observational 
(cohort, case-
control or cross 
sectional) studies 
that provide 
comparative 
information on 
presence of risk 
factors in women 
with or without 
CPP 
There were 122 studies (in 111 articles) of 
which 63 (64,286 women) evaluated 54 
risk factors for dysmenorrhoea, 19 (18,601 
women) evaluated 14 risk factors for 
dyspareunia and 40 (12,040 women) 
evaluated 48 factors for noncyclical CPP. 
Age less than 30 years, low BMI, smoking, 
early menarche (<11 years), longer cycles, 
longer duration of bleeding or heavy 
menstrual flow, nulliparity, premenstrual 
syndrome, sterilisation, PID, sexual assault, 
emotional difficulties, psychological 
symptoms and somatisation were 
associated with increased risk of 
dysmenorrhoea. Younger age at first 
childbirth, exercise and oral contraceptives 
and were associated with reduction in the 
risk of dysmenorrhoea. Age less than 50 
years, peri/post menopausal state, PID, 
sexual abuse, anxiety and depression were 
found to be associated with dyspareunia. 
Drug/alcohol abuse, miscarriage, heavier 
menstrual flow, PID, previous caesarean 
section, pelvic adhesions/other pathology, 
childhood physical or sexual abuse, 
lifetime sexual abuse, anxiety, depression, 
hysteria, psychosomatisation were 
associated with an increased risk of 
noncyclical pelvic pain 
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Objective B: To examine the variation in current indications and surgical techniques for performing 
laparoscopic uterine nerve ablation (LUNA) in Europe and assess the effect of operator experience on practice 
as also to explore gynaecologists’ ‘prior’ beliefs on effectiveness of LUNA 
4 Gynaecologists 
in the UK and 
rest of Europe 
Structured 
questionna
ire  
Indications and 
techniques for 
LUNA across 
Europe 
 
 
Survey The questionnaire was returned by 719 
(38% of 1870) of the gynaecologists 
contacted and 173 (24%) performed 
LUNA. Indications for LUNA were similar 
across UK and rest of Europe. The 
European group performed LUNA more 
often (62% vs. 21%), completely transected 
the uterosacral ligaments (56% vs. 36%) 
and ablated at a distance of more than 2 cm 
from its cervical insertion (50% vs. 21%) 
more frequently than the UK group. More 
experienced gynaecologists performed 
LUNA more for dyspareunia (46 % vs. 
26%) and endometriosis (67% vs. 47%) 
and they performed complete transection 
(45% vs.26%) more often than their less 
experienced counterparts. 
 
5 Gynaecologists 
collaborating in 
LUNA trial 
Structured 
questionna
ire  
‘Prior beliefs’ 
on effectiveness 
of LUNA 
 
Survey The most widely held ‘prior’ belief, 
reflected in both questionnaire and 
numerical responses was that LUNA would 
have a small beneficial effect on pain. The 
credible limits of this belief were 
compatible with large reductions in pain as 
60% of respondents believed a three-point 
improvement on VAS to be plausible. The 
standard deviations of expected mean 
change in VAS due to LUNA ranged from 
0.52 to 1.64.  
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Objective C: To determine the effectiveness of neuroablation in CPP by means of a systematic review and 
develop a protocol for a prospective randomised controlled trial to assess the effectiveness of LUNA in CPP 
6 Women 
undergoing 
laparoscopy 
for CPP 
Neuroablative 
procedures 
(LUNA or 
presacral 
neurectomy 
[PSN]) versus 
no 
neuroablation 
Pain relief  
Adverse effects 
Cochrane SR Nine RCTs were included in the systematic 
review. There were two trials with open 
presacral neurectomy (PSN); all other trials 
used laparoscopic techniques. For the 
treatment of primary dysmenorrhoea, 
LUNA at 12 months was better when 
compared to a control or no treatment (OR 
6.12; 95% CI 1.78-21.03). The comparison 
of LUNA with PSN for primary 
dysmenorrhoea showed that at 12 months 
follow up, PSN was more effective (OR 
0.10; 95% CI 0.03-0.32). In secondary 
dysmenorrhoea, along with laparoscopic 
surgical treatment of endometriosis, the 
addition of LUNA did not improve the pain 
relief (OR 0.77; 95% CI 0.43-1.39) while 
PSN did (OR 3.14; 95% CI 1.59-6.21). 
Adverse events were more common for 
PSN than procedures without PSN (OR 
14.6; 95% CI 5-42.5). 
 
7 Women with 
CPP who 
need 
diagnostic 
laparoscopy 
LUNA versus 
No LUNA 
during 
laparoscopy  
Improvement in 
CPP, quality of 
life and sexual 
function 
Multicentre randomised 
controlled trial protocol 
Interim analyses in 2004 have 
recommended continued recruitment. A 
total of 410 women have been randomised 
(September 2004). The two groups are 
comparable in age, parity, type of chronic 
pelvic pain (CPP) and VAS baseline 
scores. 
 
 
8.2 Implications for clinical practice 
• Prevalence of dysmenorrhoea (12 studies) is 59% (95% CI 49.1-71%), of dyspareunia 
(11 studies) is 13.3% (95% CI 8.8-20.3%) and of noncyclical pain (2 studies) is 6.2% 
(95% CI 3-12.6%). This precise estimation of disease burden should be considered by 
policy makers when planning gynaecological services. 
• Key gynaecological and psychosocial factors associated with CPP should be targeted 
in clinical evaluation of women with this symptom to individualize their management. 
• There is variation in the surgical techniques of performing LUNA in Europe and the 
techniques vary according to operator experience. This variation may impact on 
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effectiveness of LUNA. LUNA trial when completed will shed light on effectiveness 
according to technique. 
• Among gynaecologists, there is a variation in beliefs about the effects of LUNA on 
pelvic pain, ranging from substantial benefit to slight harm. Gynaecologists may take 
this into account when judging the results of the LUNA trial, which may affect the 
uptake of LUNA trial’s findings. 
• The evidence to recommend the use of nerve interruption in the management of 
dysmenorrhoea, regardless of cause, is currently insufficient. This information should 
form part of patient’s counselling at present. 
 
8.3 Implications for research practice 
• Substantial differences or even complete absence of definitions, together with 
differences in age ranges of the populations studied, complicate the interpretation of 
prevalence of CPP. The surveys should use the validated measurement tools for 
validity and comparability of the results 
• Use of retrospective studies which are subject to incomplete or selective recall of 
previous events, inappropriate exposure comparisons in some studies, use of non-
standard measurement tools with questionable validity or reliability, selecting control 
groups from women consulting for other conditions in the same setting, who did not 
have assessment like laparoscopy, non use of explicit definition for CPP and other 
such factors reduce the ability to confidently investigate causation. Future 
epidemiological studies should ideally be prospective, with explicit definitions of the 
outcome and representative of the general population.  
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• The development of non-invasive diagnostic tools for some of the underlying somatic 
conditions that may account for CPP will help with unraveling of some of the risk 
factors further. If treatment of pathology in CPP shows no better outcome than without 
treatment, then probably there is role for trials in psychological interventions. It would 
be rational to design intervention studies of use of psychological counseling, 
antidepressants and other modifiable factors in chronic pelvic pain. 
• Methods of documenting distribution of beliefs about likely effects of a treatment need 
further development. It would also be interesting to compare the graphical and textual 
methods of collecting “Bayesian priors” and explore the factors that potentially will 
lead to better representation of the clinicians’ opinions 
• The uncertainty about the effectiveness of neuroablation in CPP indicates that 
scientific clinical trials are the best way to resolve uncertainty. Another efficient 
alternative would be an individual patient data metanalysis of all the existing trials and 
ongoing studies  
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